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The aim of the studies described in this thesis was to investigate the function and 
regulation of the bile salt export pump (BSEP; ABCB11): the protein that is 
responsible for the transport of bile salts from the liver to the bile. Just before the 
start of this thesis project it was shown that mutations in the gene encoding BSEP are 
the cause of an inherited liver disease, progressive familial intrahepatic cholestasis type 
2 (PFIC-2). In chapter 2, one of these mutations is studied in detail, an aspartate to 
glycine change at amino acid position 482 (D482G) of this 1,321 amino acid-long 
protein. Although this mutation does not interfere with the transport function of 
BSEP, it gives rise to very low BSEP protein levels in vivo. Most likely, the cellular 
quality control machinery recognizes this protein as “mutant” and rapidly degrades it 
before it can reach its functional destination, the canalicular membrane.  
Chapter 3 describes that the transcription of the human BSEP gene is regulated by its 
substrates, the bile salts, via the transcription factor Farnesoid X Receptor (FXR). 
FXR functions as a heterodimer with another transcription factor, namely the 
Retinoid X Receptor or RXR. Whereas bile salts are the ligands of FXR, 9-cis retinoic 
acid (9cRA), a vitamin A derivative, is the ligand for RXR. Chapter 4 describes the 
importance of vitamin A/9cRA in BSEP regulation.  
FXR and bile salts regulate many genes, mostly involved in cholesterol, bile salt and 
lipoprotein metabolism. In recent years, also FXR-target genes have been identified 
that appear to be unrelated to these cellular processes. To obtain insight in the 
different processes that are regulated by bile salt-activated FXR, a microarray analysis 
was performed using the human hepatoma cell line HepG2, with and without 
overexpression of rat Fxr. In chapter 5, we identified fibrinogen alpha, beta and 
gamma as possible new FXR target genes. This finding shows that FXR regulates a 
broad range of different cellular processes. This is essential information for future 
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1.1 General introduction 
The liver is regarded the chemical factory of our body. One central function is the 
production of bile. Bile is crucial for digestion as well as the clearance of hydrophobic 
toxic compounds. The liver is equipped with specialized transporter proteins that are 
responsible for maintaining a constant flow of bile to digestive tract. Malfunctioning 
of these transporters is the cause of cholestasis and jaundice. This chapter gives an 
overview of the function and regulation of the transporters involved in bile formation 
and their malfunctioning during inherited and acquired cholestatic diseases. 
1.1.1 The liver 
The liver is the second largest organ of the body and in human weighs approximately 








Fig. 1-1 Schematic overall view of the blood flow and bile flow from and to the liver. Nutrient-
rich blood from the intestine and oxygen-rich blood enter the liver via the portal vein and 
hepatic artery, respectively. Blood leaves the liver via the hepatic vein. Bile, produced by the 
liver, is stored in the gallbladder and is secreted into the intestine via the common bile duct. 
Arrows indicate the flow of blood or bile. 
 
Approximately 75% of the blood supply to the liver is accounted for by the portal 
vein coming from the small intestine, stomach, pancreas and spleen. The other 25% 
flows through the hepatic artery. The blood leaves the liver via the hepatic vein (Fig. 
1-1). The liver is involved in carbohydrate metabolism, fat and lipid metabolism, 
protein metabolism, transformation of drugs and vitamins, and detoxification. The 









liver produces bile, which helps digestion and secretion of waste products. It is 
collected from the hepatic bile ducts in the gall bladder and is secreted into the 
intestine via the common bile duct (Fig. 1-1). The liver plays a role in glyconeogenesis 
and glycogenolysis; it stores glycogen and releases it on demand. The liver also stores 
other nutrients and vitamins. It synthesizes certain plasma proteins, like albumin 
(major contributor to colloid osmotic pressure of plasma, transporter of hormones, 
bilirubin, fatty acids, etc.), fibrinogens (blood clotting) and other coagulation factors. 
It synthesizes lipoproteins, cholesterol and bile salts. In addition, the liver plays a role 












Fig. 1-2 Schematic view of the fine structure of the liver. The hepatocytes are arranged in 
plates. They form a physical barrier between the blood in the sinusoids and the bile in the 
canaliculi. The bile canaliculi are formed by the apical membranes of the hepatocyte. The sheet 
of endothelial cells, lining the sinusoid, is fenestrated for the passage of small molecules 
between blood and hepatocyte. Kuppfer cells, stellate cells, and pit cells are also present in the 
sinusoids. The stellate cells are located in the space of Disse. This space between the 
endothelial wall and the hepatocytes contains and drains tissue fluid. The bile canaliculi merge 
into the larger bile ducts, which are lined by the cholangiocytes. The direction of blood flow 
and bile flow are indicated by arrows and arrowhead, respectively. 
 
The liver consists of different cell types: parenchymal cells (hepatocytes), endothelial 
cells, Kuppfer cells (macrophages), stellate cells (fat-storing and/or fibrotic cells), pit 
cells (natural killer cells) and oval or progenitor cells (Fig. 1-2). The vast majority of 
the cells in the liver are the hepatocytes. These cells carry out the primary functions of 










1.1.2 The liver units 
There are three ways for dividing the liver in functional units: (1) the "classic" liver 





Fig. 1-3 The liver units: 1) The hexagonal shape displays the classic hepatic lobule, with the 
central vein in the center and the portal triads at the border. 2) The portal lobule indicated by a 
triangle, with the portal triad in the middle and bordered by the central veins. 3) The diamond-
shaped hepatic acinus bordered by central veins and portal triads. 
 
Traditionally, the liver was divided in "classic" liver lobules, based on macroscopic 
morphology. The liver lobule is a hexagonal structure surrounded by connective 
tissue. Branches of the central vein lay in the center of the liver lobule. Hepatocytes 
are arranged in layers that radiate from the central vein to the portal triads on the 
corners, which consist of branches of the portal vein, the hepatic artery and a bile 
duct. The liver lobule unit emphasizes the drainage of blood by the central vein. 
The portal lobule unit places the portal triad in the center of a triangle of which the 
corners are branches of the central vein (Fig. 1-3) and emphasizes the blood supply by 
the portal vein and hepatic artery and the bile drainage by the bile duct. Bile, formed 
by the hepatocytes and secreted into the bile canaliculi is collected into bile ductules 
and drains into the bile duct of the portal triad. 
The third classification is that of the hepatic acinus. The boundaries of this diamond-
shaped structure are formed by two branches of the central vein and the portal triads 
of two adjacent liver lobules. This unit emphasizes the secretory function of the liver. 









1.1.3 The hepatocyte 
Hepatocytes are the main functional cells of the liver. They are responsible for the 
formation of bile, the metabolism of carbohydrates, proteins, fats, lipids, drugs and 
toxins, the synthesis of cholesterol, lipoproteins and plasmaproteins, detoxification, 
and storage of different substances like glycogen, fat and vitamins. Hepatocytes are 
especially enriched in smooth and rough endoplasmic reticulum, ribosomes, 
mitochondria, peroxisomes and lysosomes to adequately perform the many liver 
functions. Hepatocytes are polarized epithelial cells forming a physical barrier between 
sinusoidal blood and bile. The basolateral membrane is in contact with the sinusoidal 
blood and is the site for uptake of compounds. The apical membranes of adjacent 
cells form a lumen: the bile canaliculus. Tight junctions divide the plasma membrane 
in a basolateral domain and an apical domain. The vectorial transport of substances 
from sinusoidal blood to bile is mediated by specific transport proteins.1,2. A selection 
of these (human) proteins is shown in Fig. 1-4. Sinusoidal bile salt uptake is facilitated 
by NTCP and the OATP's in humans and Ntcp and Oatp's in rodents. The 
Na+/K+ATPase maintains the required electrochemical gradient. Biliary secretion of 
bile salts and other biliary compounds are carried out by BSEP, MDR3, MRP2, 
MDR1, ABCG5/G8, and FIC1 (in rodents these are Bsep, Mdr2, Mrp2, Mdr1a/1b, 
Abcg5/g5, and Fic1 respectively. The precise functions of these proteins are discussed 












Fig. 1-4 The hepatocyte houses specific transport proteins for mediating the vectorial transport 
from blood to bile of various compounds. Some of these are shown here. Bile salts are taken 
up from the sinusoidal blood by NTCP and the OATP's. The Na+/K+ATPase maintains the 
required electrochemical gradient. Bile salts are secreted into the bile canaliculus by BSEP and 
also MRP2. Bile salt secretion triggers the release of phosphatidylcholine and cholesterol, 
which are supplied by MDR3 and ABCG5/G8 respectively. The best-known ABC transporter, 
MDR1, is involved in the elimination of bulky amphiphatic organic anions. Under cholestatic 
conditions, members of the ABCC family, the MRP's, are up-regulated and may function as an 












The formation of bile is an important function of the liver. Bile is a body fluid, mainly 
containing water, electrolytes, and organic molecules including bile salts, 
phospholipids, cholesterol, and bilirubin. It flows through the biliary tract and via the 
gallbladder (except in rat) into the intestine. Bile secretion into the intestine has two 
main functions: (1) bile salts are important for digestion of dietary lipids and uptake of 
fat-soluble vitamins (A, D, E, and K); (2) it is the major route for the elimination of 
surplus cholesterol, waste products, bilirubin, drugs and other toxic components. 
Bile secretion is an osmotic process. The major driving force for bile formation is the 
secretion of bile salts at the canalicular membrane of the hepatocyte, the so-called bile 
salt-dependent bile flow. Canalicular secretion of reduced glutathione (GSH;3) also 
contributes to bile flow, the bile salt-independent bile flow. 
The biliary tract begins in the liver: the hepatocytes secrete bile into the bile canaliculi, 
these canaliculi merge into the bile ducts of the portal triad. The bile ducts merge into 
the common bile duct that allows bile to drain directly into the duodenum when it is 
needed for digestion. During fasting, bile is temporarily stored and concentrated in the 
gallbladder. Storage in the gallbladder is, however, redundant since a gallbladder is 
completely absent in rats and in humans it may be removed without any consequence. 
 









Fig. 1-5 The two pathways of bile salt synthesis: the classic pathway and the alternative 
pathway. The classic pathway starts with the conversion of cholesterol into 7α-
hydroxycholesterol in the endoplasmic reticulum, while the alternative pathway starts in the 
mitochondrion with the conversion into 27α-hydroxycholesterol. Both pathways end in the 
peroxisomes resulting in the primary bile salts cholic acid and chenodeoxycholic acid. 
1.1.5 Bile salts 
Bile salts are exclusively synthesized in the liver and are formed as natural end 
products of cholesterol metabolism. They are amphiphatic molecules, which means 
that bile salts have both water-soluble (hydrophilic) and water-insoluble (hydrophobic 
sides) characteristics. This dual nature enables bile salts to carry out their function. 









Bile salts facilitate the emulsification of lipids and subsequently help the actual 
digestion by lipases. In addition, bile salts help to solubilize and transport lipids by 
forming so-called micelles. Micelles are composed of bile salts and lipids (fatty acids, 
cholesterol, and monoglycerides) that are water-soluble, thus enabling transport of 
lipids and a great variety of other hydrophobic compounds. 
In humans, the two most abundant bile salts are cholic acid (CA) and 
chenodeoxycholic acid (CDCA), which are referred to as primary bile acids. The 
primary bile acids are synthesized from cholesterol either via the classic (also called the 
neutral) pathway, which is also the predominant pathway in human, or the alternative 
(also called the acidic) pathway (Fig. 1-54). 
The first step of the classic pathway is established by the enzyme cholesterol 7α-
hydroxylase and involves a modification of the ring structure. This reaction takes place 
in the endoplasmic reticulum. The first step of the alternative pathway takes place in 
the mitochondrion, where the enzyme sterol 27-hydroxylase modifies the sterol side 
chain. The classic pathway produces both cholic acid and chenodeoxycholic acid, 
while the alternative pathway produces predominantly chenodeoxycholic acid. Some 
enzymatic conversions take place in the cytosol. The final reactions in the formation 
of the primary bile acids occur in peroxisomes. Prior to excretion into bile, the bile 
acids are conjugated to taurine or glycine and are now referred to as bile salts. The 
ultimate fate of the conjugated bile salts is secretion into the intestine. There, 
approximately 95 % of the conjugated bile salts are reabsorbed and are transported 
back to the liver via the portal blood circulation. In the liver, they are taken up again 
by the hepatocytes for re-secretion into bile. This recycling process is referred to as 
the enterohepatic circulation of bile salts. Every day, approximately 4 grams of bile 
salts cycle about 6 times between liver and intestine. And although this enterohepatic 
circulation of bile salts is very efficient, 5% (approximately 1 gram per day) is lost each 
cycle via fecal secretion. This loss is compensated for by de novo synthesis by the liver. 
As discussed before, the primary function of bile salts is their role as detergents to 
keep dietary fats and fat-soluble vitamins available for metabolism, and to remove 
hydrophobic compounds form the body, including cholesterol and toxins. In recent 
years, however, bile salts have been shown to perform several crucial signaling 
functions in the mammalian cell as well. For example, they function as highly selective 
mediators of gene transcription.5 This is accomplished by binding and activation of 
the transcription factor Farnesoid X Receptor (FXR).6,7 Many genes, involved in bile 
salt, cholesterol and lipoprotein metabolism are regulated by bile salt-activated 
FXR5(see section 1.5.2). In addition, bile salts are now known to play an important 
role in regulation of apoptosis8 and in intracellular signal pathways involving protein 










Table 1-1. Hepatic transporters involved in bile flow. Indicated are their localization, 
substrates, relation to inherited diseases, regulation during acquired cholestasis, and 
transcriptional regulation. 
 








SM Bile salts 
 





SM Organic anions, Bile 
salts, Bilirubin 
(conjugates) 
  HNF1α 
OATP-A 
(SLC21A3) 
SM Organic anions, Bile 
salts, Bulky organic 
cations 
   
OATP8 
(SLC21A8) 
SM Organic anions 
Bile salts(?) 




SM Organic anions    
Oatp1 
(Slc21a1) 
SM Bile salts, Organic 
anions/cations 




SM Bile salts, Organic 
anions/cations 




SM Organic anions 
Bile salts 
 ↓ HNF1α 
BSEP/Bsep 
(ABCB11/Abcb11) 
















CM Phosphatidylcholine PFIC3 
ICP 








MDR1 / Mdr1a/1b CM Bulky amphiphatic 
organic anions 
Anti-cancer drugs 









Abbreviations: SM: Sinusoidal Membrane; CM: Canalicular Membrane; PFIC: Progressive 
Familial Intrahepatic Cholestasis, BRIC: Benign, Recurrent Intrahepatic Cholestasis, ICP: 
Intrahepatic Cholestasis of Pregnancy. 
↑: expression is up-regulation; ↔: expression is unaltered; ↓: expression is down-regulated 









1.2 Hepatic bile salt transport proteins 
The formation of bile is driven by the vectorial transport of solutes from the 
sinusoidal blood into the hepatocyte and from the hepatocyte into the bile canaliculus. 
Since hepatocytes form a physical barrier between sinusoidal blood and canalicular 
bile, the transport of compounds from blood to bile is carried out by specialized 
carrier systems. The hepatocyte houses various proteins, located in the sinusoidal and 
canalicular membranes, which mediate this transport (Table 1-1). 
1.2.1 Basolateral or sinusoidal transport proteins 
The hepatocyte is equipped with several transport proteins to extract metabolites, 
drugs and other compounds from the blood circulation. Sinusoidal uptake of 
compounds is mediated by members of the superfamily of solute carriers (SLC). SLC 
transport proteins are passive transporters, ion coupled transporters or exchangers 
(Fig. 1-6). These proteins use the electrochemical gradient to facilitate transport of 
solutes across the membrane. Currently, the superfamily of human solute carriers 
comprises 43 families and 298 genes (http://www.bioparadigms.org/slc/intro.asp). A 
member of a specific SLC family is assigned to that family if it has a protein sequence 






SLC transporters ABC transporters
321
 
Fig. 1-6 Members of the SLC superfamily and members of the ABC transporter family are 
involved in the transport of compounds across the sinusoidal and apical membranes of the 
hepatocyte. The SLC transporter family comprises ion coupled transporters (1), exchangers (2), 
and passive transporters (3). ABC transporters need the energy from ATP hydrolysis for 
transport and are therefore active transporters (4). (Adapted from11) 
 
In the basolateral membrane of the hepatocyte, two families are important for bile salt 
uptake: (1) SLC family 10, the sodium bile salt cotransport family with 6 members;12 
and (2) SLC family 21 or O, the organic anion transport family, with 11 members.13 
The Na+-dependent taurocholate cotransporting polypeptide (NTCP in human, Ntcp 










importer.14,15 It is exclusively expressed in the liver,15 where it is present at the 
basolateral membrane of the hepatocyte.16 Its membrane topology predicts 7 
membrane spanning regions, with the N-terminus outside and the C-terminus inside 
the cell14. NTCP preferentially transports conjugated bile salts17 and are transported in 
a Na+-dependent manner via cotransport of Na+. The Na+/K+ATPase maintains the 
Na+gradient required for this transport. Recently, it has been shown for rat Ntcp that 
it is also able to transport sulfobromophthalein in a Na+-dependent manner.18 
Sulfobromophthalein is an organic anion that is used as a diagnostic tool in the 
assessment of hepatic function. Thus, the substrate specificity of Ntcp is possibly not 
as narrow as previously considered. 
The Na+-independent uptake of bile salts is mediated by members belonging to the 
SLC21 or SLCO family (the Organic Anion-Transporting family), also known as the 
OATP's. Four OATP's are expressed in human hepatocytes: OATP-C, OATP8, 
OATP-B, and OATP-A. The first three are (possibly) involved in bile salt uptake. 
OATP-C (or SLC21A6) is exclusively expressed in liver19,20 and was initially designated 
as the liver-specific organic anion transporter. This protein is the major Na+-
independent bile salt importer and also transports unconjugated bilirubin and its 
conjugates21. OATP-A (SLC21A3) is expressed in many tissues, including liver, but is 
most important in the blood-brain barrier and transports organic anions, bile salts, and 
bulky organic cations.22 OATP-8 (SLC21A8) expression is, like that of OATP-C, 
restricted to the liver.23 There is some controversy whether this protein transports bile 
salts or not.24 OATP-B ( SLC21A9) is expressed in various tissues, with the highest 
expression in the liver, but there is no experimental evidence that it transports bile 
salts.24 
In rodents, three Oatp's are described to be involved in the Na+-independent uptake 
of bile salts: (1) Oatp1 (Slc21a1) which is expressed in liver, kidney and choroid 
plexus25; (2) Oatp2 (Slc21a5) is also expressed in liver and kidney,25,26 and (3) Oatp-4 
(Slc21a10) which is expressed only in the liver.27 
Under cholestatic conditions when serum bile salt levels are high, the expression of 
members of the ABCC family is induced to protect the hepatocyte by exporting bile 
salts.28-31 From this protein family, Multidrug Resistance Proteins 1, 3, and 4 are 
located in the sinusoidal membrane and have been shown to be capable of 
transporting bile salts.32-35 Concurrently, these proteins are proposed to function as an 
overflow efflux system for accumulated bile salts during cholestasis. 
1.2.2 Canalicular bile salt transport 
Transport from the hepatocyte across the canalicular membrane occurs against a steep 
concentration gradient. It is predominantly mediated by members of the Adenosine 
Triphosphate (ATP)-binding cassette (ABC) transporter superfamily. Contrary to the 
SLC transporters, ABC transporters are active transporters: they couple cellular energy 
to the transport of substrates across membranes. In the case of ABC transporters, the 
energy comes from the hydrolysis of ATP (Fig. 1-6). A typical ABC transporter 
protein consists of two halves connected by a linker-peptide (Fig. 1-7). Each half 
contains a so-called nucleotide-binding domain and a transmembrane domain. The 
nucleotide-binding domain, located at the cytoplasmic side of the membrane, is the 









place for ATP binding and hydrolysis and is characterized by the presence of the 
conserved Walker A and B motifs and the signature or C motif.36 The transmembrane 
domain consist of 6 to 11 membrane spanning α-helices and determines the substrate 
specificity of the protein.37 Up to now, 48 human ABC transporters are known and 
divided in seven subfamilies, designated A to G 
(http://nutrigene.4t.com/humanabc.htm). Members of three of these subfamilies (B, 


















Fig. 1-7 Schematic structure of three different ABC transporters. Full transporters like MRP1 
and BSEP contain two transmembrane domains and two NBD's. A half transporter like 
ABCG5 contains only one transmembrane domain and one NBD. The number of membrane 
spanning α-helices in the transmembrane domain may vary. For example, the N-terminally 
transmembrane domain of MRP1 contains 11 membrane-spanning α-helices. While the two 
transmembrane domains of BSEP contain 6 membrane spanning α-helices each. 
 
Conjugated bile salts are excreted into bile by the Bile Salt Export Pump (BSEP in 
human, Bsep in rodent; ABCB11; previously known as sister of P-glycoprotein or 
SPGP).38-40 BSEP belongs to the ABCB subfamily and is specifically expressed in the 
liver where it is the main determinant of bile salt-dependent bile flow. While BSEP 










Resistance Related Protein 2 (MRP2 in human, Mrp2 in rodent; ABCC2) is able to 
mediate the transport of sulfated and glucorinated bile salts.41,42 Besides the liver, it is 
also expressed in kidney and duodenum.43 MRP2 mediates the transport of many 
other glutathione-, glucuronate-, and sulfate-conjugated anions, among which its 
primary function as transporter of conjugated bilirubin. In addition, it also transports 
anticancer drugs (hence its name) and reduced glutathione.44-47 MRP2 is the main 
determinant of the bile salt-independent bile flow. 
In response to canalicular bile salt secretion, phosphatidylcholine and cholesterol are 
released from the outer leaflet of the canalicular membrane and, together with bile 
salts, form micelles, thereby protecting the bile duct epithelium from the detergent-
effects of bile salts. The Multidrug resistance 3/2 protein (MDR3 in human and Mdr2 
in rodents; ABCB4) functions as a phospholipid flippase and mediates the transfer of 
phosphatidylcholine from the inner leaflet of the hepatocanalicular membrane to the 
outer leaflet.48,49 It is predominantly expressed in the liver, but also in muscle, heart, 
and spleen.50-52 
Surplus cholesterol is eliminated from the body via bile. On the one hand, through 
conversion of cholesterol to bile salts, and on the other hand, through direct transport 
from the hepatocyte to the bile. Two members belonging to the ABCG family, 
ABCG5 and ABCG8, are involved in biliary cholesterol transport.53,54 These proteins 
are so-called half transporters: they contain only one transmembrane domain 
(consisting of 6 membrane-spanning α-helices  and one NBD (Fig. 1-7). Half 
transporters need to form homodimers or heterodimers to be a functional transporter. 
ABCG5 and ABCG8 are expressed in liver and small intestine,55 and need to be co-
expressed for canalicular targeting and biliary cholesterol secretion.56,57 
The best-known ABC transporter is a member of the ABCB subfamily: the Multidrug 
Resistance protein 1 or P-glycoprotein (MDR1 in human; mice and rats have two 
homologues: Mdr1a and Mdr1b). This transport protein was first designated as P-
glycoprotein since its presence correlated with the altered drug permeability of mutant 
(drug resistant) Chinese hamster ovary cells.58 Transfection of the MDR1 gene is 
sufficient to generate multidrug resistant cells.59 MDR1 is expressed in the apical 
membranes of various tissues, such as the brain, kidney, intestine, placenta, and 
liver.50,60,61 In normal human liver, MDR1 is lowly expressed and is involved in the 
elimination of bulky amphiphatic organic anions, including various drugs. 
Besides the ABC-transporters, the canalicular membrane contains also a P-type 
ATPase, FIC1 or ATP8B1 that is involved in bile salt homeostasis. FIC1/ATP8B1 is 
expressed in liver (canalicular membrane of hepatocytes, apical membrane of 
cholangiocytes) and pancreas, but to a much higher level in the small intestine (brush 
border62,63). The precise function of FIC1 is not clear yet. It has been suggested that it 
is a translocator of amino-phospholipids.63 The suggestion that FIC1 is involved in the 
transport of bile salts62 has been contradicted by a recent study from Harris et al.64 
that suggests that FIC1 does not function as a bile salt transporter, so the precise 
function of this protein remains elusive. However, FIC1 does affect bile salt 
homeostasis. For example, loss of the murine Atp8b1 gene65 results in elevated serum 
bile salt levels. In addition, absence of human FIC1 is associated with reduced FXR, 
the bile salt sensor.66,67 









1.2.3 Intracellular bile salt transporters 
Bile salts taken up from the sinusoids have to be transported across the hepatocyte to 
the canalicular membrane. However, little is known about this intracellular transport. 
It is assumed that it is not vesicular-, but carrier-mediated, involving bile salt binding 
proteins.68 In addition, membrane proteins are probably needed to transport bile salt 
intermediates during the multi-organellar processes of de novo bile salt synthesis. 
Enzymes involved in this process reside in the endoplasmic reticulum, mitochondria, 
cytoplasm, or peroxisomes, illustrating the need for transport systems. Little is known 
about the proteins involved in this process. 
1.2.4 Other transporters involved in the enterohepatic circulation 
of bile salts 
The enterohepatic circulation of bile salts requires that bile salts are reabsorbed from 
the intestinal lumen to the blood. The process takes place in the terminal ileum. Na+-
dependent uptake of bile salts is accomplished by the ileal Apical Sodium-dependent 
Bile acid Transporter (ASBT) in the apical membrane of enterocytes.69,70 In rodents, 
Oatp3 may add to the intestinal bile salt reabsorption through a Na+-independent 
process.71 In enterocytes, bile salts bind to the Ileal Bile Acid-Binding Protein 
(IBABP)72 and are transported across the basolateral membrane by the Ostα-Ostβ 
heterodimeric transporter.73 
1.3 Inherited diseases associated with hepatic 
transport functions  
In recent years, important progress has been made in our understanding of the 
function of hepatic transport proteins and their role in development of cholestasis. 
The elucidation of the genetic defect of various inherited forms of progressive 
cholestasis has been instrumental to show the crucial function of various transporters 
in bile salt homeostasis. 
1.3.1 Progressive Familial Intrahepatic Cholestasis 
A severe type of cholestatic liver disease is Progressive Familial Intrahepatic 
Cholestasis (PFIC). PFIC is inherited in an autosomal recessive manner, and becomes 
manifest during early childhood, and, when untreated, may result in liver failure. At 
least three subtypes have been recognized: PFIC 1, 2, and 3. 
1.3.2 Progressive Familial Intrahepatic Cholestasis type 1 
PFIC1 was first called Byler’s disease, since the first PFIC patients described were 
descendants of the Amish Jacob Byler.74,75 PFIC1 is characterized by jaundice, severe 
itching, high serum bile salt concentration, low biliary bile salt concentration, and low 
serum γ-glutamyl transpeptidase (γ-GT) level. It is caused by mutations in the FIC1 or 
ATP8B1 gene,62,76 which has been mapped to chromosome 18q21-2277. To date, 54 
different mutations in the FIC1 gene have been documented to cause PFIC1.78 One 
of these mutations, G308V, was commonly detected in patients with Byler’s disease 










a milder form of cholestasis compared to PFIC1 patients carrying the same 
mutation.65 
Despite extensive in vivo and in vitro experiments using human and mouse FIC1/Fic1, 
it is still unclear what the molecular function of the FIC1 protein is. The clinical 
features of PFIC1 clearly indicate a role in bile formation. However, FIC1 itself seems 
not capable of transmembrane transport of bile salts. Recently, Chen et al.66 showed a 
relationship between the loss of FIC1 and reduced activity of FXR. In addition, 
reduced FXR levels were also shown in a PFIC1 patient.67 FXR is a bile salt-activated 
transcription factor (see below) controlling the expression of genes encoding proteins 
involved in bile salt biosynthesis and transmembrane transport. Reduced FXR levels 
would lead to reduced canalicular secretion of bile salts by the bile salt export pump 
(BSEP), ultimately resulting in the cholestasis. However, the mechanism that is 
responsible for the specific decrease in FXR levels in the absence of FIC1 remains to 
be elucidated. 
1.3.3 Benign Recurrent Intrahepatic Cholestasis type 1 
Mutations in the ATP8B1 gene may also cause autosomal recessive inherited Benign 
Recurrent Intrahepatic Cholestasis type 1 or BRIC1.62,79 While PFIC1 presents in early 
infancy, BRIC manifests itself during adolescence and early adulthood and is 
characterized by recurrent episodes of cholestasis. Deletions, frame shifts and 
nonsense mutation appear to lead to PFIC1, while missense mutations, which could 
result in suboptimal protein expression/activity, appear to lead to BRIC.62 
Intrahepatic cholestasis of pregnancy has also been associated with BRIC.80 
1.3.4 Progressive Familial Intrahepatic Cholestasis type 2 
Some non-Amish PFIC patients, who displayed characteristics of PFIC1 patients of 
the Amish kindred, could not be mapped to the same locus as FIC1.81-83 In addition, 
morphological differences were found between these two groups of patients. PFIC1 
patients have coarsely granular bile and bland intracanalicular cholestasis, while PFIC2 
patients have amorphous bile and neonatal hepatitis.82 The PFIC2 locus on 
chromosome 2q2484 corresponds with the ABCB11 gene, encoding the Bile Salt 
Export Pump.85 In vivo experiments support these findings. Disruption of the murine 
Abcb11 gene results only in mild intrahepatic cholestasis,86 but leads to severe 
cholestasis when combined with cholate-feeding.87 Several mutations have been 
described which lead to loss of ABCB11 expression.88 The missense mutations lead to 
disturbed trafficking, decreased expression, and defective or decreased transport.89-91 
We have studied this for the aspartate to glycine mutation at position 482 that appears 
to result in a functional, but highly unstable and temperature-sensitive protein (chapter 
391). Mutations like the D482G are clinically very interesting, because they may pave 
the way for new therapies, aimed at the restoration of expression of mutant -but 
functional- proteins at the correct subcellular location. 









1.3.5 Benign Recurrent Intrahepatic Cholestasis type 2 
Recent studies show that the cause of benign recurrent intrahepatic cholestasis is not 
restricted to mutations in FIC1 but may also result from mutations in ABCB11 and 
other, yet unknown, genes. BRIC patients from 20 families were found to have no 
mutations in the FIC1 gene. Subsequent sequencing of the ABCB11 gene revealed 
that 11 patients (from 8 different families) contained mutations in this gene. Similar to 
BRIC1, BRIC2 is caused by missense mutations as well as one putative splice site 
mutation. Remarkably, one patient appeared to be homozygous for the E297G 
mutation that was previously reported to cause PFIC2. Thus, other genetic and/or 
environmental factors play a role in the symptoms associated with reduced BSEP 
function. This study also shows that there appears to be at least one more locus for 
autosomal recessive BRIC and PFIC with low serum GGT.92 In addition, there are 
indications that single nucleotide polymorphisms in the ABCB11 gene may be 
involved in intrahepatic cholestasis of pregnancy.93 
1.3.6 Progressive Familial Intrahepatic Cholestasis type 3 
The third subtype, PFIC3, is different from type 1 and 2 in that serum γ-GT level is 
high, biliary phospholipids are absent, serum bile salt level is normal, and the presence 
of extensive bile duct proliferation, cirrhosis and fibrosis.94,95 The lack of biliary 
phospholipids pointed to an impaired MDR3 (ABCB4) function, the ABC-transporter 
that acts as a flippase for phospholipids. Indeed, PFIC3 patients lack MDR3 
expression, due to mutations in the MDR3 gene94,95 MDR3 mutations may also be a 
cause of intrahepatic cholestasis of pregnancy95,96 and of cholesterol gallstone 
disease.97,98 
1.3.7 Dubin-Johnson syndrome 
The Dubin-Johnson syndrome is an autosomal recessive disorder with a relative 
benign character. This syndrome is not life threatening and no specific treatment is 
required. The syndrome was first described by Dubin, Johnson, Sprinz and Nelson, 
hence its name.99 The only symptom of Dubin-Johnson syndrome is a benign form of 
jaundice throughout the patient's life. Patients with this disease lack the bilirubin 
transporter, MRP2 (ABCC2), due to mutations in the corresponding MRP2 gene.100,101 
The secretion of conjugated bilirubin and other anionic conjugates to bile is impaired, 
but the transport of bile salts into bile is normal. The bilirubin(-conjugates) 
accumulate in liver and blood, causing the  jaundice. The Dubin-Johnson syndrome is 
phenotypically similar to transport deficient (TR-) rats,44 a strain that occurred 
naturally and lacks Mrp2 expression.102 Several mutations in the MRP2 gene have been 
described in Dubin-Johnson syndrome patients101,103 and in (TR-) rats.104 Some of the 
human MRP2 mutations were studied in detail. Dubin-Johnson-causing mutations 
may result in impaired transport activity, deficient maturation and/or impaired sorting 
of the transporter.105-107 The expression of another MRP isoform, MRP3 (ABCC3), is 
up-regulated when MRP2 function is impaired.30,108 MRP3 is located in the basolateral 
membrane of the hepatocyt and this up-regulation may compensate for the impaired 











Sitosterolemia is an autosomal recessive lipid disorder. It is characterized by 
accumulation of plant sterols (mainly sitosterol, hence the name) in blood and tissues, 
due to enhanced sterol absorption, reduced biliary sterol secretion and reduced 
cholesterol synthesis.109,110 In 1974, this disorder was described by Bhattacharyya and 
Connor111 as a lipid storage disease in two affected sisters. Other clinical features are 
cholesterol deposits (xanthomas) in skin, tendons, and coronary arteries, leading to 
premature atherosclerosis.111-113 The disease is caused by mutations in the ABCG5/G8 
genes which are located at chromosome 2p21.55,114,115 ABCG5 and ABCG8 are half 
transporters and function as a heterodimer. This explains why in PFIC1 patients, 
mutations in one of the genes is enough to result in Sitosterolemia. Studies performed 
with mice that are defective of either Abcg5 or Abcg8 confirmed these 
observations.116,117 Indeed, loss of only Abcg5 is sufficient to result in symptoms of 
Sitosterolemia. In these mice, plant sterol concentrations in plasma are elevated.116 
Similarly, disruption of Abcg8 leads to loss of biliary cholesterol secretion, although 
biliary sitosterol secretion appeared to be preserved.117 
1.4 Hepatic transporter regulation during acquired
 liver disease 
The expression of transport proteins is also affected during acquired liver disease. 
These represent by far the more common causes of cholestasis. The hepatic responses 
to the different forms of acquired liver diseases generally serve to protect the 
hepatocyte against the toxic effects of accumulated bile salts and other bile 
compounds. Several acquired forms of liver disease can be distinguished: primary 
biliary cirrhosis, primary sclerosing cholangitis, inflammation-induced intrahepatic 
cholestasis (caused by sepsis, drugs, hormones, and alcohol), and extrahepatic biliary 
obstruction (caused by gallstones or tumors). Several animal models are used to study 
the expression of hepatic transporters during intrahepatic or extrahepatic cholestasis 
(for reviews: 2,118). These models are detailed below. 
1.4.1 Endotoxin-induced cholestasis 
Sepsis is often associated with cholestasis. Lipopolysaccharide (LPS), a bacterial cell 
wall component, is the key mediator that is responsible for the development of 
cholestasis. It induces the release of inflammatory cytokines by the Kupffer cells in the 
liver, which, in turn, have major effects on protein expression in the hepatocyte.  
The endotoxin-treated rodent is an animal model to study this type of acquired liver 
disease. In the endotoxemic rat, the bile salt transport to the bile is strongly impaired, 
leading to cholestasis.119 This is associated with major effects on expression of bile salt 
uptake transporters in the hepatocyte. Ntcp and Oatp's are simultaneously down-
regulated, while expression of the bile salt export system, Bsep, is maintained.28,120-123 
The multidrug resistance proteins are either maintained (Mdr1a and Mdr2) or elevated 
(Mdr1b and Mrp1). 









Another characteristic of sepsis is jaundice, probably as a consequence of impaired 
bilirubin transport. This is indeed explained by the rodent-model: in the endotoxemic 
rat, the bilirubin transporter Mrp2 is down-regulated.28,124 
The regulation of transporter expression may be different between human and rodent. 
For example, in both human and rat MRP2. Mrp2 expression is down-regulated, but 
in humans this is accomplished post-transcriptionally, while in rat it is regulated at the 
transcriptional level.31,125,126 In addition, human BSEP expression is decreased in liver 
slices treated with LPS, while rat Bsep expression is unaltered after the same 
treatment.126  
1.4.2 Estrogen-induced cholestasis 
Cholestasis may also be associated with pregnancy or caused by oral contraceptives. 
The animal model for studying this type of cholestatic condition is 17α-
ethinylestradiol (EE)-treatment of rodents. In EE-treated rats, both sinusoidal and 
canalicular bile salt transport systems were affected. The protein levels of Ntcp, 
Oatp1, Oatp2, Oatp4, Bsep, and Mrp2 were all decreased.122,127,128 Mdr1a/b 
expression levels remain unchanged.122 As in endotoxin-induced cholestasis, 
Na+/K+ATPase activity was also reduced.129 Another important mechanism that 
effects efficient bile salt transport from the hepatocyte is the fact that the estrogen 
metabolite, estradiol-17beta-D-glucuronide, inhibits the Bsep transport activity 
directly. This may be an even more significant factor than alterations in expression 
levels.40 Bsep has a very high transport capacity. Reduction in Bsep protein levels is 
therefore not necessarily associated with reduction of the canalicular bile salt secretion 
rate.130 
1.4.3 Bile duct ligation 
The animal models described above are models for intrahepatic cholestatic conditions. 
Ligation of the common bile duct is an animal model for extrahepatic obstructive 
cholestasis. The most common cause of extrahepatic obstructive cholestasis is the 
presence of gallstones. In extrahepatic obstructive cholestasis, bile ducts are blocked, 
leading to accumulation of bile in the liver, which in turn results in liver damage and 
eventually in liver failure. 
Gap junctions disappear in bile duct-ligated rats,131 leading to an altered physical 
barrier between portal blood and bile. Expression of Oatp1, Oatp4, Bsep, Mrp2, and 
Mrp6 are down-regulated,29,121,122,127,132-134 while expression of Mdr1a, Mdr1b, Mrp3, 
and Mrp4 are up-regulated29,30,122,135,136. Mrp3 and Mrp4 are both able to transport 
sulfated bile salts and their up-regulation may serve as escape route for bile salts in 
order to protect the hepatocyte from toxic levels of bile salts.29,33,136 
1.5 Transcriptional regulation of hepatic transport
 proteins 
Expression of proteins involved in bile formation and homeostasis is tissue-specific 
with selective expression of liver-specific and intestine-specific transporters. In 










maintain bile flow and formation. As discussed above, various disease conditions 
(sepsis, inflammation, obstruction by gallstones) and drugs/hormones effect 
regulation and function transporters. The mechanisms involved can be divided into 
(1) transcriptional regulation of genes encoding transporters (this section) and (2) 
various forms of regulation at the post-transcriptional (protein) level (section 1.6). 
1.5.1 Tissue-specific expression of transporters 
Tissue-specific expression is controlled by tissue-specific transcription factors. The 
liver is enriched in Hepatocyte Nuclear Factors (HNF's). Of this family of 
transcription factors, HNF1α and HNF4 are involved in transcription of hepatic 
transporters.137,138 HNF1a is involved in transcriptional regulation of Ntcp, Oatp1, 
Oatp2, OATP-C, OATP8, and Oatp4.139-141 Another hepatocyte nuclear factor, Hnf4α 
(NR2A1142) is important in hepatocyte differentiation and expression of transcription 
factors, including Hnf1α, as shown in mice.143 Hnf4α null mice die during 
embryogensis,143 but a study with conditional Hnf4α -/- mice shows that absence  of 
the hepatic expression of this transcription factor, leads to  reduced levels of Ntcp, 
Oatp1, and Mdr2, while that of Bsep was slightly increased.144 Thus, hepatocyte 
nuclear factor 1α and 4α perform important roles in hepatic transporter expression. 
The family of CCAAT/enhancer-binding proteins (C/EBP) are other important 
hepatic transcription factors (for review: 145). C/EBPβ regulates transcription of the 
MRP2 gene,146 while an intact C/EBP element is necessary for maximal 
transactivation of the Ntcp promoter by the transcription factor Rarα.147 Ntcp gene 
transcription is also regulated by Hex.148 Hex is a homeobox-containing protein that is 
necessary for the normal development of the liver.149 The Stimulating Protein 1 is an 
ubiquitously expressed transcription factor.150 This factor is involved in the hepatic 
expression of MDR1, Mdr1b, and Mdr2.151-153 
1.5.2 Modulation of transcription by NHR's 
Nuclear hormone receptors (NHR's) are ligand-activated regulatory proteins and 
belong to the superfamily of receptors for steroid, retinoids, vitamin D and thyroid 
hormones (for reviews see: 154,155). This superfamily consists of seven subfamilies, 
designated 0 to 6. They bind to DNA as monomers, homodimers or heterodimers. 
Members of this family share a common protein structure, which consists of a ligand-
binding domain and a DNA-binding domain. The retinoic X receptor α (RXR, α: 
NR2B1, β: NR2B2) is the central dimerization partner for many of the family 
members. The ligands of nuclear hormone receptors are metabolites or drugs that 
regulate the transcription of genes involved in metabolism and/or transmembrane 
transport of the ligand itself. The vitamin A derivative, 9-cis retinoic acid is the natural 
ligand for RXR (NR2B1).156,157 The fact that a vitamin A derivative functions as a 
crucial mediator of gene transcription emphasizes the importance of vitamin A for a 
wide range of physiological processes. 
Several nuclear hormone receptors are involved in transcriptional regulation of hepatic 
transport proteins. The central factor in regulating bile salt homeostasis is the 
farnesoid X receptor (FXR; encoded by NR1H4). FXR is expressed in liver, kidney, 









intestine, and adrenal gland,158 and is activated by bile salts.6,159 Several hepatic 
transporters are directly regulated by this nuclear receptor together with RXR. Both 
human and rat BSEP/Bsep expression has been shown to be positively regulated by 
FXR.160-162 Indeed, targeted disruption of Fxr in mice leads to decreased expression of 
Bsep. Cholate-feeding could not counteract this decrease.163 The FXR/RXR 
heterodimer has been described as a permissive. This means that 9-cis retinoic acid 
activates the dimer and has an additive effect on the activation by bile salts.164,165 
However, we show in chapter 4 that for BSEP transcription this is not the case. In 
fact, 9-cis retinoic acid antagonized the effects of bile salts BSEP transcription in vitro. 
In vivo experiments show that Bsep transcription is especially sensitive to elevated bile 
salt levels in vitamin A deficient conditions. These findings described in chapter 4 
emphasize the important role of vitamin A especially during cholestasis, when vitamin 
A absorption is compromised. 
More and more genes are discovered that are regulated by FXR, including other 
transporter genes: MRP2,166 OATP8,167 and MDR3.168 FXR also regulates the 
expression of another nuclear hormone receptor: small heterodimer partner 1 or SHP-1 
(NR0B2),163,169 which is expressed in liver, small intestine, spleen, adrenal gland, ovary, 
and testis.170,171 SHP-1 is not a typical nuclear hormone receptor since it lacks a DNA-
binding domain. SHP-1 performs its function through interaction with other receptors 
by which it inhibits transactivation mediated by these receptors.170 For example, Shp-1 
inhibits the binding of the Retinoic Acid Receptor (RAR or NR1B1) which is essential 
for expression of Ntcp169,172 Shp-1 also inhibits the activity of the nuclear receptor 
liver receptor homologue 1 (LRH-1, NR5A2) and thereby represses the expression of 
the bile salt synthesis-enzyme cholesterol 7α-hydroxylase.169 Rar is ubiquitously 
expressed173 and is activated by all-trans retinoic acid.174 Another target gene for RAR 
is Mrp2.147  
The human MRP2 gene promoter is transactivated by three nuclear receptors:166 
besides FXR, these are the Pregnane X Receptor (PXR; NR1I2) and the Constitutive 
Androstane Receptor (CAR; NR1I3). All three transcription factors activate MRP2 
transcription via an everted repeat separated by 8 bases. Thus, the response elements 
appear to be less factor-specific as previously assumed. Pxr is mainly expressed in liver 
and intestine, and its ligands are a variety of xenobiotics,175-177 but also the more toxic 
bile salts like lithocholic acid.178,179 Pxr also regulates transcription of Oatp2,178,180 
MDR1,181 and MRP3182. CAR is predominantly expressed in liver and differs from the 
other nuclear hormone receptors because it transactivates the transcription of target 
genes in a constitutive manner, i.e. without binding of a ligand, hence the name 
constitutive androstane receptor.183-185 However, a number of CAR activators, 
including phenobarbital, have been identified to modulate CAR regulation.186 
Therefore, CAR may be considered to be a xenobiotic sensor like PXR.187 Murine 
Mdr2 expression is regulated by the peroxisome proliferator-activated receptor alpha 
(PPARα; NR1C1).188 It is expressed mainly in liver, kidney and heart,189,190 and its 
ligands include fatty acids and fibrates.191,192 PPARα interacts with another nuclear 
receptor, liver x receptor alpha or LXRα (NR1H3) in a yeast two-hybrid system and 










expressed194 and has been identified as a receptor for the cholesterol metabolites, 
oxysterols.195 Together with the other oxysterol receptor, LXRβ (NR1H2), LXRα 
transactivates Abcg5 and Abcg8 gene expression.196 
1.5.3 Regulation of transcription factors during cholestasis 
During cholestasis the protein expression of several hepatic transport proteins is 
altered. Some of these alterations are caused by down-regulation or up-regulation of 
the expression of transcription factors. Murine Fxr mRNA and activity is down-
regulated upon LPS administration.197 For example, Ntcp and Mrp2 are down-
regulated during endotoxin-induced cholestasis.28,120,124 Studies have shown that 
cytokines, released in response to endotoxin, suppressed the expression of the 
proteins198 by reducing the formation of RARα/RXRα complexes.147 An important 
survival pathway for cells during cholestasis is represented by Nuclear Factor kappa B 
(NFκB). This transcription factor is activated by cytokines.199 NFκB regulates the 
transcription of many genes.199 These genes encode proteins that are involved in so-
called anti-apoptotic pathways. NFκB induction due to inflammatory cholestasis may 
explain the increased expression of Mdr1 during cholestasis, since NFκB is involved 
directly in the transcription of Mdr1b.200 During estrogen-induced cholestasis, down-
regulation of the expression of Ntcp and Oatp's may be attributed to a reduced DNA-
binding activity of Hnf1, C/EBP and Pxr.128 
1.6 Post-translational regulation of transport proteins 
The capacity for transport across the hepatic and intestinal epithelial cells is not only 
regulated by transcriptional processes, which primarily determine the protein levels. 
Especially hepatocytes may store significant amounts of transporter proteins in 
cytoplasmic pools. These cytoplasmic pools may be rapidly targeted to the plasma 
membrane to increase the transport capacity when needed. This may occur, for 
instance, immediately after a meal when there is a high demand for bile salt to aid in 
digestion. Besides acting as FXR-activators, bile salts are also involved in the short-
term regulation of the bile salt transport capacity across the canalicular membrane. 
Taurocholate stimulate bile secretion by translocation of Bsep, but also Mdr1a/b, 
Mdr2, and Mrp2 from intracellular pools to the canalicular membrane.201,202 Similar 
effects are described for dibutyryl-cyclic AMP, a synthetic second messenger. Cyclic-
AMP also stimulates recruitment of Ntcp to the basolateral membrane.203 The bile salt 
tauroursodeoxycholate is used in treatment of certain cholestatic conditions because 
of its known choleretic actions.204 This bile salt activates the PKC and/or MAPK 
pathways, thereby enhancing the insertion of Bsep205 and Mrp2206 into the canalicular 
membrane. 
Compounds may also directly inhibit the transport of  endogenous substrates, thereby 
limiting the transport capacity. This is one of the underlying causes of drug-induced 
(hepato)toxicity. For instance, cholestasis may develop during treatment with 
cyclosporin A, rifamycin SV, rifampicin or glibenclamide. These drugs have been 
shown to directly inhibit the transport activity of BSEP.207-209 Such drugs may either 









selectively inhibit one transporter or have effects on other ABC-transporter family 
members as well. 
1.7 Concluding remarks 
Cholestasis has various causes, for instance genetic mutations, sepsis, gallstones or 
drugs to name a few. But the primary clinical manifestations are the same: jaundice, 
pruritus, and in the end liver damage. A common cellular phenomenon in cholestatic 
diseases is dysfunction of transport proteins in bile formation. In the last decade much 
progress has been made in understanding the function and regulation of hepatic 
transport proteins. The knowledge gathered gives insight in the mechanism of bile 
formation in health and disease, and may help to further develop successful therapies 
for cholestatic diseases. 
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2.1 Abstract  
Background/Aims: Progressive familial intrahepatic cholestasis type 2 (PFIC-2) patients 
have a defect in the hepatocanalicular bile salt secretion. The disease is caused by 
mutations in the bile salt export pump (BSEP). Ten different missense mutations have 
been described. In this study, we analysed the effect of the D482G PFIC-2 mutation 
on BSEP function. 
Methods: Adenosine triphosphatase (ATPase) and taurocholate transport assays were 
performed with full-length mouse Bsep (mBsep) with and without the D482G 
mutation. The effect on expression and subcellular sorting was studied in HepG2 
cells, stably expressing enhanced green fluorescent protein (EGFP)-tagged mBsep 
proteins.  
Results: The D482G mutation did not significantly affect the taurocholate transport 
activity of mBsep, even though the bile salt-inducible ATPase activity of the mutant 
protein was slightly reduced. Protein expression and canalicular sorting were strongly 
affected by the D482G mutation. Mutant EGFP-mBsep protein was only partly 
glycosylated and detected in both the canalicular membrane and the cytoplasm. At 
30°C, the mutant mRNA and protein levels were strongly increased, and the protein 
was predominantly glycosylated and efficiently targeted to the canalicular membrane. 
Conclusions: These data suggest that PFIC-2 patients with the D482G mutation express 
a functional, but highly unstable, temperature-sensitive bile salt export pump. 










Bile salts are the main solutes in bile. They are produced from cholesterol in the 
hepatocyte and are secreted across the canalicular membrane in an adenosine 
triphosphate (ATP)-dependent manner.1-3 They are transported from the hepatocyte 
to bile by the bile salt export pump (BSEP).4 BSEP is an ATP-binding cassette 
transporter belonging to the ATP-binding cassette (ABC) subfamily B. It consists of 
two intracellular nucleotide-binding domains (NBD) and twelve transmembrane 
domains in two homologous halves, connected by a linker peptide. The NBD’s are 
highly conserved and contain the Walker A and B motifs5 that are involved in the 
binding and successive hydrolysis of ATP. The NBD’s are located at the cytoplasmic 
face of the membrane and couple the hydrolysis of ATP to substrate translocation 
across the membrane. The membrane spanning domains are thought to determine the 
substrate specificity of transport.6 
Progressive familial intrahepatic cholestasis (PFIC) is an inherited autosomal recessive 
liver disease mainly occurring in infants and children. Without treatment this leads to 
cirrhosis and death from liver failure.7 At least three different forms of PFIC can be 
distinguished. PFIC type 3 is caused by mutations in the canalicular phospholipid 
transporter, multidrug resistance protein 3.8 Consequently, bile of these patients does 
not contain phospholipids. PFIC type 1 and 2 show low concentrations of biliary bile 
salts. PFIC type 1 is caused by mutations in the FIC1 gene encoding a P-type ATPase 
with unknown function.9 PFIC type 2 (PFIC-2) is caused by mutations in BSEP.10,11. 
Several PFIC-2 related mutations have been described. Eight mutations predicted 
premature truncation of the protein; the remaining (10) mutations are missense 
changes. We investigated the effects of the PFIC-2 related missense mutation D482G, 
an aspartate to glycine change at position 482,10 occurring in the first nucleotide-
binding domain of BSEP, on the adenosine triphosphatase (ATPase) activity, 
transport activity, sorting, and expression of the protein. Our results show that this 
mutation does not cause protein malfunction nor does it block the sorting of the 
protein to the canalicular membrane. In fact, the D482G mutation causes a 
temperature-sensitive reduction of BSEP protein expression, probably caused by 
reduced protein stability. 
2.3 Materials and Methods 
Stable cell lines and culture conditions 
Standard culture conditions for the human hepatoma cell line HepG2 and derivatives 
have been described before.12 Ten µmol/l dibutyryl-adenosine 3’,5’-cylcic 
monophosphate (Roche Diagnostics GmbH, Mannheim, Germany) was added to the 
culture medium to stimulate the formation of bile canalicular vacuoles (BCV’s) by 
HepG2 cells. HepG2 and derivatives were grown at 30°C to increase enhanced green 
fluorescent protein (EGFP)-mBsep mRNA and protein expression. HepG2 cells were 
transfected with pEGFP-C1-mBsep[WT] or pEGFP-C1-mBsep[D482G] using the calcium 










Molecular biological techniques 
Escherichia coli Top 10 (Invitrogen BV, Breda, the Netherlands) was used for 
propagation and amplification of plasmid DNA. Recombinant DNA procedures were 
performed as described.13 Plasmid DNA was isolated using the EndoFree® Plasmid 
Maxi Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s 
instructions. 
For heterologous expression of the full-length mouse Bsep (mBsep) gene in Sf21 insect 
cells, an EcoRI fragment encoding the full-length mBsep open reading frame was 
excised from MSCV-SPGP-IRIS-GFP14 and inserted into EcoRI-digested 
pFASTBAC1 (Invitrogen BV, Breda, the Netherlands). For expression of EGFP-
tagged mBsep in HepG2 cells, full-length mBsep was amplified by polymerase chain 
reaction (PCR) using primers mBsep-start and mBsep-stop digested with HindIII and 
KpnI and inserted into pEGFP-C1 (BD Biosciences Clontech, Palo Alto, CA) digested 
with the same enzymes. Site-directed mutagenesis was performed using the 
QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) to introduce 
the D482G mutation in pFASTBAC1-mBsep and pEGFP-C1-mBsep (primers used: 
mD482Gsense/antisense). All DNA constructs were confirmed by DNA sequencing. 
Details about the primers used for cloning and site-directed mutagenesis are available 
from the authors. 
Production of mouse Bsep-enriched membrane vesicles 
Sf21 insect cells were cultured at 27ºC in Insect-XPRESS™ medium (Biowhittaker, 
Verviers, Belgium), supplemented with 5% (vol/vol) fetal bovine serum, 5 mg/ml 
penicillin G, 5 mg/ml streptomycin, and 10 mg/m neomycin (Invitrogen BV, Breda, 
the Netherlands). Recombinant mBsep bacmids and baculoviruses were generated 
using the Bac-to-Bac Baculovirus expression system, according to the manufacturer's 
instructions (Invitrogen BV, Breda, the Netherlands). The virus titer, culture time and 
multiplicity of infection were optimised to obtain comparable amounts of wild type 
and mutant mBsep proteins. Recombinant insect cells were collected and membrane 
vesicles were isolated as described.15 The membrane vesicles were snap frozen in 
liquid nitrogen and stored at –80°C until further use. 
ATPase activity 
The ATPase activity of recombinant mouse Bsep was determined by a colorimetric 
assay essentially as described,16 except that 2 mmol/l EGTA, 2 mmol/l dithiothreitol, 
5 mmol/l sodium azide, and/or 200 µmol/l orthovanadate (inhibitor of ATPase 
activity)/30 µmol/l taurocholate were also added to the ATPase reaction mixture. The 
ATPase activities were calculated by the difference in nmol Pi produced between 10 
and 20 min. 
Bile salt transport assay 
Transport of 0.5 µmol/l [3H]-labeled taurocholate (TCA, Perkin Elmer Life Sciences, 
Zaventem, Belgium) was measured by a rapid filtration technique, as described.17 In 









control experiments, ATP was replaced by adenosine β,γ-methylene triphosphate 
(AMP-PCP, Roche Diagnostics GmbH, Mannheim, Germany). 
Reverse-transcription polymerase chain reaction (RT-PCR) 
Total RNA was isolated as described.12 Messenger RNA (mRNA) levels of EGFP-
mBsep and ribosomal 18S RNA levels were quantified using the ABI PRISM 7700 
sequence detector (Applied Biosystems, Foster City, CA). Real-time RT-PCR 
conditions were as described.18 Primers and probes used for 18S, mBsep, and EGFP 
are available from the authors. 
Western blot Analysis 
Sf21 membrane fractions and total HepG2 cell lysates were separated by 7.5% sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)19 and analysed by 
Western blotting.20 Protein concentrations were determined using the Bio-Rad Protein 
Assay system (Bio-Rad GmbH, Munich, Germany) using bovine serum albumin as 
standard. Polyclonal antibodies used, were raised against GFP (gift from Prof. dr. W.-
H. Kunau, Bochum, Germany) and BSEP (k1221). Mouse anti-rabbit alkaline 
phosphatase (Sigma-Aldrich Chemie Gmbh, Steinheim, Germany) and bromo-
chloroindolyl phosphate/nitro blue tetrazolium (Roche Diagnostics GmbH, 
Mannheim, Germany) were used for detection according to manufacturer’s protocols. 
Protein expression was quantified by scanning the blots using an Image Master VDS 
system (Pharmacia Biotech, Uppsala, Sweden). 
Deglycosylation assay 
For protein deglycosylation, total HepG2 protein extracts were incubated with peptide 
N-glycosidase F (PNGaseF, New Engeland Biolabs, Beverly, MA) according to the 
manufacturer’s instructions. 
Confocal laser scanning microscopy 
For microscopical analyses, cells were cultured on coverslips and fixed using 4% 
paraformaldehyde. For immunofluorescence, fixed cells were treated with 1% Triton 
X-100 and stained for multidrug resistance-related protein 2 (MRP2, canalicular 
marker protein) using the monoclonal antibody M2-III6 (Alexis Biochemicals, Lausen, 
Switzerland), with the corresponding second antibody Alexa fluor 568 (Alexis 
Biochemicals, Lausen, Switzerland). Images were taken with a confocal laser scanning 
microscope (TCS 4D; Leica, Heidelberg, Germany) equipped with an argon/krypton 
laser and coupled to a Leitz DM IRB (Leica, Heidelberg, Germany) inverted 
microscope. 
2.4 Results 
Single amino acid changes in BSEP that cause PFIC-2 may result in inactive, 
missorted, and/or unstable BSEP protein. The D482G mutation is present in the first 










2-1). Due to experimental difficulties with expression of full-length human BSEP,22,23 
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Fig. 2-1 Sequence alignment of the human and mouse BSEP NBD’s. The amino acid 
sequences of human and mouse BSEP are highly conserved. The Walker A and B motifs and 
the ABC signature are shown in bold. The aspartate (D) at position 482 is conserved between 
human and mouse BSEP. Note that it is also conserved in the second NBD. ClustalW was 
used to align the NBD’s of human and mouse BSEP. 
The mBsep[D482G] protein is still functional as a bile salt 
transporter 
Wild type and D482G mutant mBsep were expressed at comparable levels in Sf21 
insect cells (Fig. 2-2A, insert). Membrane preparations containing mBsep[WT] (white 
bars) showed similar ATPase activities as control membranes (grey bars; 12.2 ± 0.85 
versus 15.8 ± 0.95 nmol Pi·min-1·mg-1 protein; Fig. 2-2a). However, upon addition of 
30 µmol/l taurocholate (TCA), the ATPase activities of the mBsep[WT] vesicles were 
enhanced (41.8 ± 2.14 nmol Pi·min-1·mg-1 protein), which was not observed with the 
control membranes (16.4 ± 1.47 nmol Pi·min-1·mg-1 protein). Addition of 
orthovanadate, an inhibitor of the ABC-transporter ATPase activity, fully inhibits the 
TCA-dependent ATPase activity in the mBsep-containing membranes. Similar results 
were obtained with membrane fractions containing mBsep[D482G] (black bars). The 
constitutive ATPase activity of these membranes was 13.7 ± 1.47 nmol Pi·min-1·mg-1 
protein and the TCA-dependent ATPase activity (29.1 ± 1.45 nmol Pi·min-1·mg-1 









protein) was blocked by orthovanadate. This shows that the ATPase activity of both 
WT and D482G mBsep are stimulated by the substrates of the transporter. The bile 
salt transport activity of the wild type and mutant mBsep is shown in Fig. 2-2b. Both 
mBsep[WT]- and mBsep[D482G]-vesicles show similar TCA uptake rates (32.7 ± 1.5 


























































































Fig. 2-2 The D482G mutation does not block the ATPase and transport activity of mBsep. (a) 
Membrane vesicles containing comparable levels of wild type or D482G mutant mBsep (insert) 
are subjected to an ATPase assay in the absence or presence of 30 µM TCA and 200 µM 
orthovanadate as described in Materials and Methods. The data are presented as mean ± SD of 
triplicate determinations in nmol liberated Pi·min-1·mg-1 total protein. Membrane vesicles 
from uninfected insect cells served as control. (b) The same membrane vesicles were subjected 
to a transport assay using [3H]-labelled TCA. Samples were taken at the indicated time points. 
The data are presented as mean ± SD of triplicate determinations in pmol TCA/mg total 










The EGFP-mBsep[D482G] is inefficiently targeted to the canalicular 
membrane in HepG2 cells 
To study the protein stability and subcellular sorting of wild type and mutant mBsep, 
we generated stable HepG2 cell lines that express these proteins, N-terminally tagged 
to the EGFP. Geneticin-resistant clones were screened for the presence of the EGFP-







Fig. 2-3 Efficient sorting of the D482G mutant mBsep in HepG2 cells is temperature-
sensitive. EGFP signal (a,d,g) is shown in green, MRP2 (canalicular) staining (b,e,h) is shown in 
red, and the combined images (EGFP + MRP2) are shown in c, f and i. Yellow staining 
indicates overlap of both signals. At 37°C, both EGFP-tagged wild type (a,c) and D482G 
mutant (d,f) mBsep sort to the BCV. However, significant amounts of the D482G mutant 
mBsep are detected intracellular (d,f). MRP2 staining (b and e) was used as marker for the 
BCV’s. Both proteins co-localise at the canalicular membrane (c and f) in polarised HepG2 
cells. When cells were grown at 30°C, the D482G mutant mBsep was solely observed in the 
BCV’s. g, EGFP; h, MRP2 and i, merged images. Insets show higher magnifications of single 
BCV's (a-c) or single polarized cells (d-f). Bar = 10 μm. 
 
As is observed with normal HepG2 cells in culture, up to 20-30% of these cells 
acquire a polarised phenotype, forming BCV’s.24 These BCV’s contain canalicular 









proteins, as shown by MRP2 staining (Figs. 2-3b, e, and h). EGFP-mBsep[WT] co-
localised with MRP2 in BCV’s of HepG2 cells (Figs. 2-3a-c), indicating that the N-
terminal EGFP-tag does not interfere with mBsep targeting. The EGFP-mBsep[D482G] 
mutant protein was detected in the BCV’s but, in addition, a considerable amount of 
protein was retained in the cytoplasm (Figs. 2-3d-f). 
The D482G mutation results in unstable and immature mBsep 
protein 
Next, we analysed the correlation between the mRNA and protein level of cells stably 
expressing EGFP-mBsep[WT] and EGFP-mBsep[D482G]. Western Blot analysis using the 
GFP antibody showed that EGFP-mBsep[WT] can be easily detected in total cell lysates 
as a protein of approximately 190 kDa (Fig. 2-4, lane 2). However, the EGFP-
mBsep[D482G] signal at this position is hardly detectable (Fig. 2-4, lane 1). In stead, a 
GFP-specific protein band is present at approximately 160 kDa in these protein 
extracts. This might be either a degradation product or, alternatively, improperly 
glycosylated EGFP-mBsep protein. Treatment of EGFP-mBsep[WT]-containing 
extracts with PNGaseF resulted in a molecular weight shift to approximately 160 kDa 
(Fig. 2-4, lane 3). PNGaseF-treatment of EGFP-mBsep[D482G] resulted in the 
disappearance of the minor 190 kDa band. The 160 kDa band remained unchanged 
(not shown). This shows that the 160 kDa EGFP-mBsep[D482G] protein band is full-
length, but improperly glycosylated protein. Moreover, the specific amount of EGFP-
mBsep[D482G] protein appeared lower than the EGFP-mBsep[WT] protein. Therefore, 
we determined the specific mRNA levels of EGFP-mBsep[WT] and EGFP-mBsep[D482G] in 
the corresponding cell lines. In contrast to the difference in protein level, the relative 
amount of EGFP-mBsep[D482G] was 4.5-fold higher compared to the EGFP-mBsep[WT] 
mRNA level (Fig. 2-5a). These data show that high mRNA levels for EGFP-
mBsep[D482G] do not give rise to similarly high protein levels, relative to the results 












Fig. 2-4 The D482G mutation leads to low levels and incompletely glycosylated mBsep 
protein. Western blot analysis using a GFP antibody of approximately 160 µg of total protein 
extracts from EGFP-mBsep[D482G] HepG2 cells (lane 1), and EGFP-mBsep[WT] cells (lanes 2 
and 3). In lane 3, the extract was treated with PNGase F. 
2.4.1 Low temperature stabilizes EGFP-mBsep 
Several examples exist of missense mutations that give rise to unstable temperature-
sensitive proteins. The best-studied example is the ΔF508 mutation in the cystic 










cultured both the EGFP-mBsep[WT] and EGFP-mBsep[D482G] HepG2 cells at 30°C and 
determined the specific mRNA and protein levels. Surprisingly, we found that the 
relative mRNA levels for both EGFP-mBsep[WT] and EGFP-mBsep[D482G] increased 
approximately 12-fold in cells grown at 30°C compared to cells grown at 37°C (Fig. 2-
5a). However, the 4.5-fold difference between EGFP-mBsep[D482G] and EGFP-
mBsep[WT] remained despite the overall higher mRNA levels. In cells grown at 30ºC, 
the protein level of both EGFP-mBsep[WT] and EGFP-mBsep[D482G] increased 
significantly when compared to cells at 37°C (Fig. 2-5b). However, the EGFP-
mBsep[D482G] showed a much stronger increase in protein level than the EGFP-
mBsep[WT]. Moreover, at 30°C the EGFP-mBsep[D482G] appeared predominantly in 
fully glycosylated form. Under these conditions, the EGFP-mBsep[D482G] protein level 
was approximately 5-fold higher than EGFP-mBsep[WT] as determined by 
densitometry. This is in good agreement with the difference in the mRNA levels, 
implying that both proteins show similar overall protein stability at 30°C. Confocal 
laser scanning microscopy revealed that at 30°C, the EGFP-mBsep[D482G] protein was 
efficiently targeted to the BCV’s (Figs. 2-3g-i). 
wild type D482G


















































Fig. 2-5 The protein level and glycosylation of the mutant BSEP is temperature-sensitive. (a) 
Total RNA from HepG2 cells expressing wild type of mutant mBsep, was isolated and 
subjected to quantitative real-time RT-PCR. Relative EGFP-mBsep mRNA levels were obtained 
by normalising to the ribosomal 18S RNA content. (b) Total protein lysates from HepG2 cells 
expressing the wild type or D482G mutant mBsep were isolated. Cells were cultured at 37 or 
30°C. The parental HepG2 cells grown at 37°C were used as control. SDS-PAGE and Western 
blotting was performed on 100 µg total protein using a GFP antibody. Unglycosylated (*) and 
glycosylated (◄) EGFP-mBSEP are indicated. 










In this study, we analysed the effect of the PFIC-2 mutation, D482G, on Bsep 
function and intracellular expression. We found that this mutation does not abolish 
the ATPase activity nor the taurocholate transport activity. However, at physiological 
temperatures, the stability, canalicular sorting, and glycosylation of the mutant protein 
are disturbed. The D482G-mutant Bsep protein appears to be temperature-sensitive. 
At 30oC, high levels of normally glycosylated, and correctly sorted Bsep[D482G] were 
detected. In this study, we also report the remarkable finding that in transfected 
HepG2 cells grown at 30°C, the mRNA levels of the heterologous expressed genes 
are over 10-fold higher compared to the same cells grown at 37°C. Concurrently, the 
corresponding proteins show significantly increased levels in cells grown at 30°C. 
Since the D482G mutation is present in the first NBD of BSEP, we first tested its 
effect on the ATPase activity. ABC transporters, like BSEP, possess an ATPase 
activity that is highly stimulated by the transported substrates. Concurrently, we found 
that the ATPase activity of full-length mouse Bsep was strongly induced by TCA. The 
ATPase activity of the mBsep[D482G]-protein was also induced by TCA, be it to a lower 
level than the WT protein. However, the reduced bile salt activation of the ATPase 
activity did not affect the TCA transport kinetics of the mutant protein. Taken 
together, these results show that the mBsep[D482G] is a functional bile salt transporter 
with biochemical characteristics comparable to the wild type protein. 
To study the effect of the D482G mutation on intracellular sorting and protein 
stability, we constructed stable HepG2 cell lines, expressing mBsep[WT] or mBsep[D482G] 
N-terminally tagged with EGFP. Detectable amounts of EGFP-mBsep[D482G] protein 
were only observed in clones with significantly (5-fold) higher mRNA levels as 
compared to EGFP-mBsep[WT]. In addition, the mutant protein was improperly 
glycosylated suggesting accumulation of the protein in the endoplasmic reticulum. 
This was confirmed by confocal laser scanning microscopy analyses, in which 
significant amounts of the EGFP-mBsep[D482G] protein were detected in a fine 
reticulum-like pattern in the cytoplasm. In contrast, the EGFP-mBsep[WT] protein was 
observed in the BCV’s and not in the cytoplasm. Collectively, our findings suggest 
that the D482G mutation results in low BSEP protein levels and that the mutant 
protein is improperly glycosylated and targeted at physiological conditions. 
A comparable effect is described for the ΔF508 mutation in the ABC transporter 
CFTR. This mutation is the most common genetic cause of cystic fibrosis. At the 
molecular level, this results in increased turnover of an otherwise active CFTR. The 
processing and stability of this mutant protein has been shown to be temperature-
sensitive.25,26 Therefore, we cultured our stable cell lines at reduced (30°C) 
temperatures and found that the mRNA level for both EGFP-mBsep[WT] and EGFP-
mBsep[D482G] increased approximately 12-fold compared to the level in cells grown at 
37°C. This strong temperature effect on transcript levels was specific for the 
heterologously expressed gene and was not observed for endogenous genes, such as 
human MDR1 and MRP1 (data not shown). Recently, a similar strong temperature-
dependent increase in the mRNA level of the tetracycline-dependent transactivator 
has been reported.27 This effect was found to be independent of the promoter used 










Therefore, it is most likely caused by increased mRNA stability. In our experiments, it 
was accompanied by strongly increased EGFP-mBsep[WT] protein levels and therefore 
may have important implications for the high level expression of heterologous 
(membrane) proteins in HepG2 cells and/or other mammalian cell types. At 30°C, 
both the mRNA and protein level of EGFP-mBsep[D482G] were approximately 5-fold 
higher than those for EGFP-mBsep[WT] mRNA level. This implies that both proteins 
show similar cellular stability at 30°C. At this low temperature, both proteins were 
efficiently glycosylated and sorted to the canalicular membrane.  
Recently, Wang et al., 2002,28 also reported on the molecular effect of PFIC-2 
mutations on BSEP function. They found that the D482G mutation reduced the 
taurocholate transport activity of rat Bsep by approximately 50% and GFP-tagged 
rBsep[D482G] was found at the apical membrane and in the cytoplasm of Madin-Darby 
canine kidney (MDCK) cells. The correlation between GFP-rBsep[D482G] mRNA and 
protein levels was not determined in detail. Our results show little or no effect of the 
D482G mutation on the BSEP transport function, but a very strong effect on protein 
stability, maturation and/or turnover. Liver-specific protein quality control 
mechanism may be present in HepG2 cells but perhaps not -or to a lesser extent- in 
MDCK cells. Another difference between our studies and those of Wang et al., is the 
use of rat versus mouse Bsep. Since the proteins are highly similar to human BSEP 
and fully conserved at the positions of the PFIC-2 missense mutations, we feel that 
both are valid model proteins to study the molecular effect of this human disease. The 
deleterious effect of the D482G mutation could therefore be due to a combination of 
reduced protein stability, canalicular sorting and substrate transport defects. With the 
recent cloning and heterologous expression of the human BSEP gene in insect cells, 
these studies may be performed with the human BSEP in the near future.22,23 
In conclusion, our data show that PFIC-2 patients with the D482G mutation express 
a functional, but highly unstable bile salt export pump. Our findings offer hopes for 
therapy: drugs that stabilise the protein may be able to restore the PFIC-2 defect. 
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The Bile Salt Export Pump (BSEP or ABCB11) mediates the adenosine triphosphate-
dependent transport of bile salts across the canalicular membrane of the hepatocyte. 
Mutations in the corresponding ABCB11 gene cause progressive familial intrahepatic 
cholestasis type 2. 
The aim of this study was to investigate the regulation of human ABCB11 gene 
transcription by bile salts. First, a 1.7-kilobase human ABCB11 promoter region was 
cloned. Sequence analysis for possible regulatory elements revealed a farnesoid X 
receptor responsive element (FXRE) at position -180. The farnesoid X receptor 
(FXR) functions as a heterodimer with the retinoid X receptor α (RXRα) and can be 
activated by the bile salt chenodeoxycholic acid (CDCA). Luciferase reporter gene 
assays revealed that the ABCB11 promoter is positively controlled by FXR, RXRα 
and bile salts in a concentration-dependent manner. Mutation of the FXRE strongly 
represses the FXR-dependent induction. Second, endogenous ABCB11 transcription 
regulation was studied in HepG2 cells, stably expressing the rat sodium-dependent 
taurocholate transporter (rNtcp). ABCB11 expression was induced by adding bile salts 
to the culture medium, and this effect was maximized by combining it with 
cotransfection of rFxr and hRXRα. Reducing endogenous FXR levels using RNA 
interference fully repressed the bile salt-induced ABCB11 expression. In conclusion, 
these results show that FXR is required for the bile salt-dependent transcriptional 
control of the human ABCB11 gene and that the cellular amount of FXR is critical for 
the level of activation of ABCB11 transcription. 










The formation of bile is an important function of the liver. Bile salts are necessary for 
the intestinal absorption of dietary fats and fat-soluble vitamins and the biliary 
elimination of surplus cholesterol and a variety of toxins. Bile salts are synthesized in 
the hepatocytes with cholesterol as the sole precursor. The secretion of bile 
components (bile salts, phospholipids) across the canalicular membrane of the 
hepatocyte to the bile duct is adenosine triphosphate (ATP)-dependent and is mainly 
performed by members of the ATP-binding cassette transporter superfamily. 
Impaired bile secretion results in cholestasis with accumulation of bile salts and other 
toxic bile components in hepatocytes and blood plasma.1,2 
Progressive familial intrahepatic cholestasis comprises a number of inherited liver 
diseases of childhood that are characterized by cholestasis and jaundice leading to 
cirrhosis3. In patients with progressive familial intrahepatic cholestasis type 2, 
cholestasis is a result of impaired secretion of bile salts into canaliculi caused by 
mutations in the ABCB11 gene.4 The ABCB11 protein (previously named sister of P-
glycoprotein or bile salt export pump) is a member of the P-glycoprotein subfamily 
and is the major canalicular bile salt transporter.5 
To maintain bile salt homeostasis, both bile salt synthesis and hepatobiliary transport 
are strictly controlled processes. For instance, at increased bile salt concentrations in 
the blood, the hepatic uptake and bile salt biosynthesis are down-regulated, whereas 
canalicular transport into bile is up-regulated.6 Recently, a number of bile salts have 
been shown to bind and strongly activate the nuclear hormone receptor farnesoid X 
receptor (FXR) at physiologic concentrations. 7,8,9 FXR is active in a heterodimer with 
the 9-cis retinoic acid receptor retinoid X receptor α (RXRα) and binds to an inverted 
repeat element with a 1-base pair spacing (IR-1) between the two 6-base pair half-
sites.10,11,12 Rat Fxr (rFxr) is expressed in liver, intestine, and kidney.10{Wang, Chen, et 
al. 1999 92 /id}{Wang, Chen, et al. 1999 92 /id} 
FXR is now believed to be the major bile salt sensor that regulates the expression of 
key enzymes in the bile salt biosynthesis pathway and bile salt transporters. Bile salt-
activated FXR up-regulates the intestinal bile acid-binding protein, a soluble protein 
that has been proposed to buffer intracellular bile salts, which may be involved in the 
transcellular transports of bile salts in enterocytes.13 Conversely, it down-regulates the 
expression of cholesterol 7α-hydroxylase (Cyp7a1), the rate-limiting step in bile salt 
synthesis from cholesterol,14 and the sodium-dependent taurocholate transporter in 
the sinusoidal membrane of the hepatocyte. Down-regulation occurs via the up-
regulation of a transcriptional repressor, the small heterodimer partner 1.15,16 
The central role of FXR in bile acid homeostasis is most elegantly shown by the 
comparative analysis of wild type and Fxr-null mice. These studies also show that Fxr 
and bile salts are involved in expression of the murine Abcb11 gene, encoding the bile 
salt export pump.17 
In this study, we investigated the transcriptional regulation of the human ABCB11 
gene by analyzing the role of its substrates, bile salts, and the nuclear receptors, FXR 










gene contains an FXR/RXRα responsive element and that the ABCB11 promoter is 
transactivated by FXR/RXRα binding.18 We show that FXR is required for the bile 
salt-induced up-regulation of human endogenous bile salt export pump expression in 
HepG2 cells, stably expressing the rat sodium-dependent taurocholate transporter 
(rNctp). Suppression of FXR expression in these cells using RNA interference 
inhibited the bile-salt dependent up-regulation of endogenous ABCB11 by bile salts. 
3.3 Experimental procedures 
Bacterial strains and cell culture 
Escherichia coli Top 10 (endA1, recA1, hsdRMS, deoR, mcrA, lacZΔM15, Invitrogen BV, 
Breda, the Netherlands) were routinely used for propagation of plasmid DNA. E. coli 
were grown in Luria Broth (Miller’s modification) medium (Sigma-Aldrich, Germany), 
containing the appropriate selection antibiotic. 
The human hepatoma cell line HepG2, and a stable derivative expressing rNtcp19 were 
cultured at 37°C in a humidified atmosphere of 5% CO2 in air in Dulbecco's modified 
Eagle medium with GlutaMAX-1, 4500 mg/L D-glucose, sodium pyruvate, 
pyridoxine supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum, 100 
U/mL penicillin G, 100 µg/mL streptomycin, 250 ng/mL fungizone and 250 µg/mL 
geneticin (for HepG2-rNtcp) (Invitrogen BV). The cell culture was passed twice a 
week. 
For a time-course analysis of endogenous ABCB11 messenger RNA (mRNA), HepG2 
cells were incubated with 100 µmol/L chenodeoxycholic acid (CDCA, sodium salt; 
Calbiochem-Novabiochem, San Diego, CA) dissolved in phosphate-buffered saline 
(PBS) for different time points. Cells were harvested for RNA isolation and 
conventional reverse-transcription polymerase chain reaction (RT-PCR) at same cell 
densities. 
Plasmids 
Chromosomal DNA was isolated from a human blood sample using the QIAamp 
DNA Blood Kit (QIAGEN GmbH, Hilden, Germany). A 1,752-base pair DNA 
fragment containing the human ABCB11 promoter (position -105 to -1857 relative to 
the translation initiation site) was amplified from chromosomal DNA using primers 
5'-CAC ACT GCC CAG ATG TGT CT-3’ and 5'-CCA ACC TCG GTT TTC ATC 
AT-3' and inserted into pGEM-T-Easy (Promega Corp., Madison, WI). The human 
ABCB11 promoter was subsequently removed from this vector by digestion with MscI 
(at –1778) and SalI (multiple cloning site pGEM-T-Easy) and inserted into SmaI-XhoI 
digested pGL3-basic (Promega Corp.) upstream of the firefly luciferase reporter gene, 
resulting in pGL3-1778. A shorter promoter construct containing base pair -105 to 
base pair -277 (pGL3-277) was generated by PCR using pGL3-1778 as template and 
the primers 5’-CCC GGT ACC GGT TTC CCA AGC ACA CTC TG–3’ and 5'-
AGG AAA GCT TCC AAC CTC GGT TTT CAT CAT-3' and inserted into pGL3-
basic, using the KpnI and HindIII restriction sites (bold). Using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, Ca), the proposed FXR responsive 









element (FXRE) site of both pGL3-1778 and pGL3-277 were mutated using primers 
5'-CTA TTT GCC TAA TTA TCA ATG TAA CTA AGG GCA GC-3' and 5'-GCT 
GCC CTT AGT TAC ATT GAT AAT TAG GCA AAT AG-3', generating pGL3-
1778Mt and pGL3-277Mt (mutated base pairs in bold). All promoter constructs were 
checked by DNA sequencing. 
Transient transfections 
HepG2-rNtcp cells19 were transfected by the calcium phosphate coprecipitation 
method.20 Plasmid DNA was isolated and purified using the EndoFree Plasmid Maxi 
Kit (QIAGEN GmbH) according to the manufacturer’s instructions. 
HepG2-rNtcp cells were seeded in 6-well plates at a density of 3 x 105 cells per well 
on day 1. On day 2, the cells were transfected with a total amount of 4 µg plasmid 
DNA in 250 mmol/L CaCl2 and 2 x HEPES buffered saline (274 mmol/L NaCl, 10 
mmol/L KCl, 10 mmol/L D+glucose, 42 mmol/L HEPES, 1.6 mmol/L 
Na2HPO4•2H2O, pH 7.05. Various combinations of plasmids were used as specified 
in the figure legends. Concentrations of the specific plasmids used for promoter 
studies were 1 µg promoter construct (pGL3-derivatives), 100 ng expression vectors 
(pCMXrFxr, pSG5hRXRα, pCMV5) 50 ng RL-TK (transfection efficiency control; 
Promega Corp.), and pGEM-5 (Promega Corp.) as carrier DNA to increase the total 
amount of plasmid DNA to 4 µg. Concentrations of the specific plasmids used for 
mRNA analysis were 1 µg expression vectors (pCMXrFxr, pSG5hRXRα, pCMV5), 
and pGEM-5 as carrier DNA to increase the total amount of plasmid DNA to 4 µg. 
On day 3, approximately 20 hours after the transfection, medium was refreshed either 
containing 100 μmol/L CDCA dissolved in PBS or PBS alone. Cells were harvested 
after 24 hours for determination of luciferase activity and after 48 hours for total 
RNA isolation. Luciferase activity was determined by the Dual-Luciferase Reporter 
Assay System  (Promega Corp.) as described by the manufacturer's protocol using an 
Anthos LUCY1 Luminometer (Anthos Labtec Instruments GmbH, Salzburg, Austria) 
with a 10-second counting window. Except for experiments including pSG5hRXRα, 
firefly luciferase activities were corrected for transfection efficiency as determined by 
the Renilla luciferase activity. Cotransfection of the pSG5hRXRα vector resulted in a 
marked (4-8-fold) increase of the Renilla luciferase activity, which is unlikely to reflect 
increased transfection efficiency. This was also evident from experiments in which the 
pGL3-basic was used in combinations with various amounts of pSG5hRXRα. Over a 
concentration range of 0 to 1 µg hRXRα vector, no significant changes were observed 
in firefly luciferase activity, whereas the Renilla luciferase activity increased 5-fold. 
Therefore, the relative firefly luciferase units were used to evaluate the effect of 
cotransfection of rFxr and hRXRα. 
RT-PCR 
Total RNA from HepG2-rNtcp cells was isolated using the SV Total RNA Isolation 










performed on 5 µg of total RNA using random primers in a final volume of 75 µL 
(Reverse Transcription System, Promega Corp.) as described previously.21 
For conventional RT-PCR, 3 µL of complementary DNA was used in a final reaction 
volume of 50 µL containing 0.5 U Taq polymerase (Eurogentec, Seraing, Belgium) and 
50 pmol of sense and antisense primers (Invitrogen BV) using a Robocycler Gradient 
96 (Stratagene). The cycling program consisted of 5 minutes at 95°C followed by 22 
cycles (glyceraldehyde-3-phosphate dehydrogenase (GAPDH)), 34 cycles (ABCB11), 
or 30 cycles (FXR) at 95°C for 40 seconds, 58°C (GAPDH) or 60°C (ABCB11, FXR) 
for 40 seconds, and 72°C for 40 seconds and 5 minutes in the last cycle. Primers used 
for GAPDH were 5'-CCA TCA CCA TCT TCC AGG AG-3' (sense) and 5'-CCT 
GCT TCA CCA CCT TCT TG-3' (antisense) and gave a product of 576 base pairs; 
for ABCB11 5'-GGA ACC AGT GTT GTT TGC CT-3' (sense) and 5'-AAC CTG 
CAC CGT CTT TTC AC-3' (antisense) and gave a product of 295 base pairs; and for 
FXR 5'-GGA ATG TTG GCT GAA TGC TT-3' (sense) and 5'-GTT GCC ATT 
TCC GTC AAA AT-3' (antisense) and gave a product of 305 base pairs. Eight micro 
liters of each PCR product was loaded on a 2% (wt/vol) agarose gel and stained with 
ethidium bromide. 
For quantitative real-time detection RT-PCR,22,23 sense and antisense primers 
(Invitrogen BV) and probes (Eurogentec) for ABCB11 and 18S were designed using 
Primer Express software (PE Applied Biosystems, Foster City, CA). For ABCB11 the 
primers and probe used were 5’-ACA TGC TTG CGA GGA CCT TTA-3’ (sense), 5’-
GGA GGT TCG TGC ACC AGG TA-3’ (antisense) and 5'-CCA TCC GGC AAC 
GCT CCA AGT CT-3' (probe), generating a 105-base pair product; for 18S 5’-CGG 
CTA CCA CAT CCA AGG A-3’ (sense), 5’-CCA ATT ACA GGG CCT CGA AA-3’ 
(antisense) and 5'-CGC GCA AAT TAC CCA CTC CCG A-3' (probe), generating a 
109-base pair PCR fragment. Both probes were 5’-labeled with 6-carboxy-fluorescein 
and quenched by 6-carboxy-tetramethyl-rhodamine. For real-time PCR, 3 µL 
complementary DNA was used in a PCR reaction in a final volume of 50 µL 
containing 900 nmol/L of forward and reverse primers and 200 nmol/L of probe, 250 
nmol/L MgCl2, 10 nmol/L deoxynucleoside triphosphate mix, 5 µL Real-Time PCR 
buffer (10x), and 1.25 U Hot GoldStar (Eurogentec). Real-time detection PCR was 
performed on the ABI PRISM 7700 (PE Applied Biosystems) initialized by 10 minutes 
at 95°C to denature the complementary DNA followed by 40 PCR cycles each of 
95°C for 15 seconds and 60°C for 1 minute. 
RNA interference 
Small interfering RNA's (saran's) specific for human FXR were designed conforming 
to the sequence AA(N19)TT, where AA and TT are present in the FXR open reading 
frame at a spacing of 19 nucleotides. Two single-stranded RNA molecules, 5’-GGG 
GAU GAG CUG UGU GUU GdTdT-3’ (sense) and 5’-CAA CAC ACA GCU CAU 
CCC CdTdT-3’ (sense) were synthesized (Dharmacon Research, Lafayette, CO). As 
control, single stranded-RNA molecules specific for the firefly luciferase gene were 
synthesized24. For annealing, 20 µmol/L of both single-stranded RNA's were 
incubated in annealing buffer (200 mmol/L potassium acetate, 30 mmol/L HEPES-









KOH, pH 7.4, and 2 mmol/L magnesium acetate) for 2 minutes at 90°C and cooled 
down to 30°C in approximately 1 hour. 
HepG2-rNtcp cells were transfected with 10 µL of 20 µmol/L siRNA duplexes using 
Oligofectamine reagent according to the manufacturer’s instructions (Invitrogen BV). 
The next day, the transfection medium was replaced by fresh culture medium 
containing 100 µmol/L CDCA. After 48 hours, cells were harvested for RNA 
isolation and conventional RT-PCR analysis as previously described. 
3.4 Results 
Cloning of the ABCB11 promoter 
Using the ABCB11 mRNA sequence AF09158225 to search the BLAST database, the 
human BAC clone AC008177 was identified to contain part of the genomic ABCB11 
locus, including the known 5'-untranslated region and the possible ABCB11 promoter 
region. Comparison of the 2 sequences showed the presence of a large (13,072 base 
pairs) intron within the 5'-untranslated region of ABCB11, 26 base pairs upstream of 
the translation initiation site. 
Fig. 3-1a shows the nucleotide sequence of ABCB11 from base pairs -1857 to +21 
(relative to the translation initiation codon, excluding the 13-kilobase intron). 
a 
                                    -1857 CACACTGCCCAGATGTGTCTGGCCAGCAT 
 -1828 GAGGGTGCAGAGGAAGACACCCTGAACTCTCCAGGGCCCTGGACAGATGGCCACTCTGTCTTCA 
 -1764 CTTTTCTCATCTATAAGATGAAGTTGTTGGATGATATATCAATATTTACAATGTTGTTTCTAGC 
 -1700 TCTAAAACTCTATGCTTTTATCTTCCCTTGGATCTTCATGGCACCAGAAGGAAAGTCTTAGGAC 
 -1636 CCTTGGACCTGTGAGCAGATCAGCTATAGTCCTGAGTTGACAAATTTCTCTTGGCATTTTTACC 
 -1572 CTTTGACTGCTGTCAATAACTTCAGCACAGCAAAGGTAGCAAAATTCTATTGGGAATCTTTTCC 
 -1508 CAATCAAAGCTACAGCCCCATAGCTGTGTTGCCTTTTTGGTTTTGTGTGAAGCAAAATTTTTTT 
 -1444 CCTGGGTCCTAATTGGTGCCAAATCCAATATTACTACATTTGCGTCAACTCAGAAGTCAACCCA 
 -1380 TTCAGTTTGCATAGAGGAAACATCTAGAAATCTTGCTTTTCTTTGCTGACCTTGATATATTTGA 
 -1316 GATTTGAACATATAATAACATATAAAATTATATGTTATAATTTTGGGTTTTATGGGCTAAGTCA 
 -1252 TAAACCATCTTATACATAAATTCCAATAGAGAAAAAATGGTGGATGCTGAATTTTAATAAAAAA 
 -1188 TTTATGACAGAGAAACCTAAAATTGAGAAAATTTGATCTTACAGTTTAATTTCTGCAAATTAAG 
 -1124 AAGCACTGGCCCATCAATTGCATTTCAGAGCACAGAGTGGAAGAAGGTTAGCACAGACTGGCAT 
 -1060 GTGGCTTCACATCTACTAGTTGTTACACCTTAGGAGGATTATTTAACCTCTCTGTGCTTCAGTT 
  -996 TCCCCAACTATAAAATAGAAATGACATGATAGCACCCAACTCCTAGGGCTGTTGAGAGGCCCAA 
  -932 ATGAGGTGATACAAATAACATTTTTGAAGTGGGCCAGGCACCCAACCAAGTCTTGACCAATGTT 
 -868 GCCTATTATTATTCATTGCTGAAGGCTGGAGTGAGAGGCATTTAGGGAAAAGTAAGCTCAGGCA 
  -804 AAGGAGAAAAAATAAGAACATTGTAGGAAAAATGGAAAGATTCACAAGAAGGGAGAGGAAGAGG 
  -740 CAGCACAAATATATTGGAGGAGCTCCACATGCTTATTTGACTCAAGACCTGTTCATTTGAACCT 
  -676 TTAGAAAATCGTTCATCTTTGCTTATACAGAGCTTCATCTGGTGTGTCCATGCCAGGGTGCAAG 
  -612 AGTTGTCTGTGCACTCAGACTTTTGAGCAAGGCTGTTTCAAATGTTCTTTTAGGGTATTTGTCT 
 -548 CCACAAAACTCTATAGCTGGGCCAGGAGCATCTGGATCCTGCAACCAGGGATTTTCCAAGAGCA 
  -484 ATCTTTTATATTGAGGGGGAAAGTTTAAAGGTATTTTTTTTTTTTGTCTTGTTATGTTTTTAAG 
  -420 TAACTTTTCACAACTACAGGCCTGTAAAAAATAAGGGTTGGGATAGCCTGAATTCCAGGGCTCT 
  -356 TGCTGGGCCCACTCTGCTCAATTTGCCTCTCGTTCCAAGGTGAATCAGCAATTTCCAAGGCCTG 
 -292 TTGACACCCTCAGAGGGTTTCCCAAGCACACTCTGTGTTTGGGGTTATTGCTCTGAGTATGTTT 
                                                FXRE            
  -228 CTCGTATGTCACTGAACTGTGCTTGGGCTGCCCTTAGGGACATTGATCCTTAGGCAAATAGATA 
 -164 ATGTTCTTGAAAAAGTTTGAATTCTGTTCAGTGCTTTAGAATGATGAAAACCGAGGTTGGAAAA 
                                                                  ↑-105 
  -100 GGTTGTGAAACCTTTTAACTCTCCACAGTGGAGTCCATTATTTCCTCTGGCTTCCTCAAATTCA 
   -36 TATTCACAGGGTCGTTGGCTGTGGGTTGCAATTACC ATG TCT GAC TCA GTA ATT CTT 











                                                  FXRE 
 hABCB11 -222 ATGTCACTGAACTGTGCTTGGGCTGCCCTTAGGGACATTGATCCTTAGGC 
 mAbcb11      ATGTCACTGAACTGTGCTAGATCTGGACTTTAGGCCATTGACCTATAAGC 
 
 hABCB11 -172 AAATAGATAATGTTCTTGAAAAAGTTTGAATTCTGTTCAGTGCTTTAGAA 
 mAbcb11      AAATAGATAGTGTTCTTAAAAAAGCCTGATTTCTGTTCAATGCTTTATTA 
 
 hABCB11 -123 TGATGAAAACCGAGGTTGG -105 




















Fig. 3-1 The human ABCB11 promoter contains an FXRE. (a) The nucleotide sequence of the 
human ABCB11 locus from base pair -1857 (first base pair upstream of the start codon is 
numbered -1) to base pair +21. The proposed FXRE (boxed) is located at base pairs -192 to -
180. A 13,072-base pair intron is located within the known 5’-untranslated region between base 
pairs -27 and -26. For numbering of the DNA, the 13-kilobase intron is not calculated. 
Position -105 indicates the 3’ end of all promoter constructs. (b) Comparison of the nucleotide 
sequences of human ABCB11 (AF091582, GI3873242) and murine Abcb11 (AF303740, 
GI10799100) promoter region. Both contain an FXRE (boxed). (c) Schematic overview of the 
human ABCB11 promoter constructs used in this study. The constructs pGL3-1778 and 
pGL3-277 are denoted according to the numbering of the sequence shown in a. The FXRE is 
indicated as a black box and which is marked with an X for the mutated constructs pGL3-
1778Mt and pGL3-277Mt. Please note that all promoter constructs used end at position -105, 
upstream of the large intron. 
 
Screening for possible binding sites for transcription factors using the TRANSFAC 
database (http://transfac.gbf.de/TRANSFAC/index.html) showed several ubiquitous 
and liver-specific transcriptional regulatory elements, including a putative FXR 
binding site at position -180 to –192 (Fig. 3-1a). The FXRE consists of an IR-1. 
Comparison of the human and mouse ABCB11 promoter sequences showed that the 
position of the FXRE is conserved in both species and that the human FXRE 
contains 2 mismatches taken the consensus sequence of the FXRE, AGGTCA (Fig. 
3-1b).10,11 









Two genomic DNA fragments comprising nucleotide –1,857 to –105 or –277 to –105 
were amplified by PCR and inserted into a luciferase reporter gene vector, resulting in 
pGL3-1778 and pGL3-277, respectively. pGL3-227 still contains the putative FXRE 
and only a minimum of other regulatory elements. Subsequently, the IR-1 sequence in 
both constructs was mutated by site-directed mutagenesis, generating pGL3-1778Mt 
and pGL3-277Mt, as schematically shown in Fig. 3-1c. 
FXR overexpression induces human ABCB11 promoter activity 
The role of the nuclear hormone receptor FXR and its activation by bile salts on the 
promoter activity of human ABCB11 was studied. HepG2-rNtcp cells were 
cotransfected with one of the promoter constructs and an expression vector for rFxr 
or a control vector. After the transfection, the cells were incubated in the presence or 
absence of the bile salt CDCA (100 µmol/L) for 24 hours. 
Transient cotransfection of either promoter construct with the control vector did not 
result in a significant increase in the (relative) luciferase activities (Fig. 3-2a, white 
bars). In contrast, cotransfection of pGL3-1778 with the rFxr expression vector in the 
absence of CDCA increased the luciferase activity 48-fold. Also, the shorter construct, 
pGL3-277, showed a similar inducibility by rFxr (33-fold). Culturing the rFxr-
cotransfected HepG2-rNtcp cells in the presence of 100 μmol/L CDCA further 
enhanced the luciferase activity to 175- to 231-fold for pGL3-1778 and pGL3-227, 
respectively. 
The level of rFxr-induced ABCB11 promoter activity was dependent on the 
concentration of CDCA in the culture medium. HepG2-rNtcp cells were 
cotransfected with the pGL3-277 and rFxr constructs and grown in the presence of 
variable amounts of CDCA for 24 hours. As shown in Fig. 3-2b, a positive correlation 
was observed between the concentration of CDCA (up to 100 μmol/L) in the growth 
medium and the level of luciferase activity. 
FXR-RXRα co-overexpression results in maximum CDCA-
induced activity of the human ABCB11 promoter 
The activity of FXR requires heterodimerization with RXRα. Therefore, we studied 
whether co-overexpression of rFxr together with hRXRα would further increase the 
CDCA-induced activity of the ABCB11 promoter. As can be seen in Fig. 3-3, 
coexpression of pGL3-1778 with rFxr and hRXRα in the absence of CDCA already 
increased the firefly luciferase activity significantly (approximately 2.5-fold compared 
to rFxr alone), probably due to the presence of endogenous ligands for these nuclear 
receptors.26,27 The presence of 100 μmol/L CDCA in the growth medium resulted in a 
further increase of 4-fold compared to rFxr and hRXRα coexpression in the absence 
of CDCA or rFxr alone in the presence of CDCA. The additive effect of hRXRα 
coexpression with rFxr on human ABCB11 promoter activity was confirmed by 
analyzing endogenous ABCB11 mRNA levels in HepG2-rNtcp cells. These data show 
that both FXR and RXRα are required for maximum CDCA-dependent induction of 





















































































Fig. 3-2 The putative FXRE is involved in the transactivation of the human ABCB11 promoter 
by rFxr and CDCA in HepG2-rNtcp cells. This transactivation is CDCA concentration-
dependent. (a) HepG2-rNtcp cells were cotransfected with the indicated luciferase reporter 
construct and either the control vector or the rFxr expression vector and treated with PBS 
alone or 100 µmol/L CDCA dissolved in PBS for 24 hours. For each promoter construct, the 
relative firefly luciferase activity was normalized using cotransfected pRL-TK. The normalized 
data are presented as fold induction over control. (b) HepG2-rNtcp cells were cotransfected 
with pGL3-277 and either the control or rFxr expression vector. Following transfection, cells 
were treated with PBS (control, rFxr) or various amounts of CDCA (rFxr). After 24 hours, 
firefly and Renilla luciferase activities were assayed and processed as described in a. 









































Fig. 3-3 FXR, RXRα and CDCA are required for maximum induction of the ABCB11 
promoter. HepG2-rNtcp cells were cotransfected with the pGL3-1778 and control, rFxr, 
and/or hRXRα expression vectors and incubated with or without 100 µmol/L CDCA for 24 
hours. The results are presented in relative firefly luciferase units (RLU). 
Mutating the putative FXRE reduces the FXR-CDCA inducibility 
of the human ABCB11 promoter 
To test whether the putative FXRE is involved in the activation of the human 
ABCB11 promoter, this site was mutated by site-directed mutagenesis, resulting in 
pGL3-1778Mt and pGL3-277Mt. Cotransfection of the rFxr-vector with pGL3-
1778Mt or pGL3-227Mt resulted in a 15- and 9-fold increase in luciferase activity, 
respectively, compared to cotransfection with the control vector (Fig. 3-2a). This 
increase was further enhanced after stimulation with 100 µmol/L CDCA to 49- and 
26-fold, respectively (Fig. 3-2a). Although the promoter activities of the mutant 
constructs were still stimulated by rFxr and CDCA, the increase was strongly reduced 
compared with the wild-type promoter constructs (26-fold vs. 231-fold for 
rFxr+CDCA-induced expression of the short promoter construct). Taken together, 
these results suggest that the putative FXRE is involved in the rFxr-mediated bile salt-










FXR-RXR co-overexpression increase the endogenous ABCB11 
mRNA level in HepG2 cells 
Our results show that rFxr and bile salts positively control the human ABCB11 
promoter element when present in a luciferase reporter plasmid. To determine the 
effect of these factors on the transcriptional control of the genomic human ABCB11 
locus, we analyzed the endogenous ABCB11 mRNA levels in HepG2 cells under 
various conditions. First, we cultured HepG2 cells in the presence of 100 μmol/L 
CDCA and determined the level of ABCB11 mRNA in time by conventional RT-
PCR. As can be seen in Fig. 3-4, ABCB11 mRNA was undetectable when HepG2 
cells were grown in the absence of CDCA (T=0) under the specified RT-PCR 
conditions (see legend to Fig. 3-4 for details). The ABCB11 mRNA gradually 
increased over 24 hours, after which it remained stable for an additional 72 hours. In 
contrast, the level of endogenous FXR did not significantly change over time. 
 









Fig. 3-4 Endogenous ABCB11 mRNA expression is up-regulated by CDCA. HepG2 cells were 
treated with 100 µmol/L CDCA for different time spans (0-96 hours). Cells were harvested at 
comparable cell densities. Five micrograms of total RNA was transcribed into complementary 
DNA and subjected to conventional RT-PCR analysis of endogenous ABCB11, FXR, and 
GAPDH mRNA levels. 
 
To determine whether the increase in ABCB11 mRNA is controlled by the amount of 
FXR (and RXRα), we transfected HepG2-rNtcp cells with rFxr and/or hRXRα 
expression or control vector, cultured them for 48 hours in the absence or presence of 
CDCA, and determined the ABCB11 mRNA level by quantitative real-time detection 
RT-PCR (Fig. 3-5). The relative amount of ABCB11 mRNA in HepG2-rNtcp cells 
increased 3.1-fold after growth in the presence of CDCA. Transfection of rFxr or 
hRXRα expression vectors alone resulted in an ABCB11 mRNA increase of 3.5- and 
1.8-fold, respectively. On incubation of these cells in the presence of CDCA, these 
levels further increased to 24.2- and 4-fold respectively, relative to HepG2-rNtcp cells 
grown in the absence of CDCA. rFxr and hRXRα coexpression gave only a moderate 









increase of 2.8-fold, which was maximally induced to more than 100-fold when these 
cells were grown in the presence of CDCA. These data confirm that, by increasing 
rFxr and hRXRα concentrations by cotransfection of HepG2-rNtcp cells, the level of 
ABCB11 mRNA is significantly up-regulated, especially in the presence of CDCA. 
Notably, the level of endogenous FXR mRNA did not significantly change on 
stimulation of HepG2 cells with CDCA (Fig. 3-4). To determine whether the CDCA-
dependent up-regulation of ABCB11 mRNA is controlled by activation of FXR, we 















































Fig. 3-5 Endogenous ABCB11 mRNA expression is maximally up-regulated by coexpression 
of rFxr and hRXRα and stimulation with 100 µmol/L CDCA. HepG2-rNtcp cells were 
transfected with the indicated expression vectors and incubated with PBS or 100 µmol/L 
CDCA. After 48 hours, total RNA was isolated and subjected to quantitative real-time RT-
PCR. The relative ABCB11 mRNA level was obtained by normalizing each sample to the 
ribosomal RNA content using the comparative CT method. 
FXR is required for CDCA-induced up-regulation of endogenous 
ABCB11 expression in HepG2 cells 
RNA interference is a novel technique to suppress the expression of specific genes in 
cultured cells. The mediators of RNA interference are siRNA molecules. siRNA's 
matching a specific gene sequence, induce the selective degradation of the mRNA of 
this gene.24,28-30 We developed siRNA probes to specifically suppress endogenous 
FXR mRNA levels in HepG2-rNtcp cells. After transfection using FXR-specific or 
control (luciferase) siRNA probes, HepG2-rNtcp cells were cultured for 48 hours in 










conventional RT-PCR. As can be seen in Fig. 3-6, FXR and ABCB11 mRNA levels 
were readily detectable in HepG2-rNtcp cells treated with the control siRNA probes 
and were similar to the levels observed in normally CDCA-induced cells (not shown). 
In contrast, cells transfected with the FXR-specific siRNA molecules showed 
significantly reduced mRNA levels of endogenous FXR, indicating specific 
suppression of the target mRNA levels. ABCB11 mRNA levels were reduced to that 
observed in untreated and uninduced cells, even though FXR mRNA was still 
detectable at this time point, albeit at significantly reduced levels. These data show that 
FXR is required for the short-term up-regulation of ABCB11 mRNA levels in 
response to elevated bile salt concentrations. Notably, a critical amount of FXR is 







Fig. 3-6 Decreasing the endogenous FXR mRNA level by RNA interference results in full 
suppression of the CDCA-dependent induction of ABCB11 mRNA expression. HepG2-rNtcp 
cells were transfected with siRNA duplexes directed against either the firefly luciferase gene 
(luc) as control or the human FXR gene (fxr) and treated with 100 µmol/L CDCA. After 48 
hours, cells were harvested and RNA isolated for conventional RT-PCR analysis of ABCB11, 
FXR, and GAPDH mRNA levels. 
3.5 Discussion 
In this study, we determined the role of bile salts and the transcription factors FXR 
and RXRα on human ABCB11 transcription encoding the liver-specific canalicular 
bile salt export pump (bile salt export pump or ABCB11). Using luciferase reporter 
gene assays, we show that the human ABCB11 promoter is transactivated by the 
coordinate action of the bile salt CDCA, FXR, and its interacting partner RXRα. 
Analysis of the transcriptional control of the genomic ABCB11 locus in HepG2-rNtcp 
cells confirmed the essential role of FXR in bile-salt-dependent up-regulation of 
human ABCB11 transcription. 
The bile salt export pump is an ATP-dependent transporter in the canalicular 
membrane of hepatocytes that transports bile salts against a steep concentration 
gradient into bile. The functional amount of ABCB11 is precisely controlled to fit the 
needs of the cell and the organism to maintain bile homeostasis. 
To analyze the transcriptional control of the human ABCB11 gene, we cloned a 1.7-
kilobase-promoter region of the ABCB11 gene. The promoter region seemed to 
contain several possible response elements for ubiquitous (activator protein 1) and 
liver-enriched transcription factors (CCAAT/enhancer-binding protein β, hepatocyte 
nuclear factor 3 β), including a putative FXRE or IR-1. The FXRE was present in the 









human and murine ABCB11 promoter regions at identical spacing from the 
translation initiation site, consistent with a ubiquitous role of FXR as an endogenous 
bile salt sensor in the mammalian liver. The FXRE sequence in the human ABCB11 
promoter does not correspond exactly to the previously described consensus sequence 
as found in the promoter region of intestinal bile acid-binding protein. However, a 
recent study demonstrated that FXR/RXRα heterodimers bind and activate a number 
of FXRE elements that differ from the consensus sequence at 1 or 2 positions. 
However, the highest affinity was observed for the consensus IR-1 sequence.11 
This study shows that FXR, RXRα, and CDCA synergistically transactivate the 
human ABCB11 promoter in HepG2-rNtcp cells. FXR alone already significantly 
induced the ABCB11 promoter activity in these cells. This is probably due to the 
endogenous production of bile salts by HepG2 cells that may activate overexpressed 
FXR.26,27 This view is supported by our finding that, in a kidney-derived cell line 
(Hek293), FXR required exogenously added CDCA to transactivate the ABCB11 
promoter (data not shown). Adding increasing amount of CDCA up to 100 μmol/L 
to the culture medium further increased the ABCB11 promoter activity, showing that 
the level of activation is dependent on the concentration of bile salts. To show that 
the putative FXRE is indeed responsible for the FXR- and bile salt-dependent 
activation, the FXRE sequence was mutated. FXR and CDCA showed a strongly 
reduced effect on transactivation of the mutant ABCB11 promoter constructs. 
However, a low but significant induction was still observed. This may be caused by a 
combination of factors, including the involvement of other liver-specific transcription 
factors, endogenous bile salts, and the excess of FXR present in the transiently 
transfected cells. The possible presence of another FXRE site is unlikely because 
other putative bile salt response elements were not found in this region. Furthermore, 
the mutant promoter constructs were almost silent in Hek293 cells after FXR/CDCA 
induction, suggesting the involvement of other liver-specific factors in activation of 
these constructs in HepG2-rNtcp cells (data not shown). Therefore, our data suggest 
that the putative FXRE indeed plays an important role in the FXR-dependent 
regulation of the ABCB11 promoter activity. 
Essentially the same results were recently described by Ananthanarayanan et al., who 
also showed that the human ABCB11 promoter is transactivated by bile salts, FXR, 
and RXRα.18 In addition, we extended our studies to the transcriptional control of the 
genomic ABCB11 locus in HepG2(-rNtcp) cells. These studies were performed to (1) 
compare and validate our results of the ABCB11 promoter studies to the 
transcriptional control of the genomic ABCB11 locus, (2) determine the kinetics of 
CDCA- and FXR-dependent transactivation of endogenous ABCB11, (3) analyze the 
effect of overexpression and underexpression of FXR on ABCB11 mRNA levels, and 
(4) evaluate the possible role of the large, 13-kilobase-long, intron in the 5’-
untranslated region of the primary ABCB11 transcript on CDCA/FXR-dependent 
regulation. 
Both conventional and real-time detection RT-PCR analysis showed that the 
endogenous ABCB11 mRNA level is significantly induced by adding CDCA to the 
medium of HepG2 cultures. Maximum induction was observed approximately 24 










stimulation), no further change in the FXR mRNA levels was observed. 
Overexpression of rFxr (by transient transfection) alone had little effect on ABCB11 
mRNA levels, but resulted in a strong increase (25-fold) when activated by CDCA in 
the culture medium. The ABCB11 mRNA levels were even further increased (more 
than 100-fold) by co-overexpression of rFxr and RXRα in the presence of CDCA. 
Reducing the level of endogenous FXR by RNA interference using siRNA molecules 
specific for human FXR led to a marked decrease in CDCA-induced activation of 
ABCB11 transcription to uninduced levels. The successful application of RNA 
interference in HepG2-rNtcp cells to reduce the mRNA level of endogenous FXR 
opened the possibility to analyze the effect of temporary reduction of transcription of 
a single gene at the cellular level. It is therefore compatible with studies on gene 
knockout mice in which the long-term effects of gene elimination are observed. In 
Fxr-null mice, the basal level of Abcb11 mRNA was reduced to 30% of wild-type mice 
and bile acid-induced up-regulation of Abcb11 mRNA (6-fold in wt mice) was 
absent.17 Our data show that reducing the level of FXR immediately results in the 
absence of bile salt-dependent up-regulation of the ABCB11 transcript and that the 
cellular amount of FXR is the major determinant of the level of bile salt-induced 
ABCB11 transcription. 
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The farnesoid X receptor/retinoid X receptor α (FXR/RXRα) heterodimer regulates 
transcription of genes involved in bile acid homeostasis, including the Bile Salt Export 
Pump (BSEP) and Small Heterodimer Partner 1(SHP). FXR is activated by bile acids and 
RXRα by 9-cis retinoic acid (9cRA). We evaluated the role of 9cRA in the expression 
of BSEP/Bsep and SHP/Shp in vitro and in vivo. 
Human BSEP and SHP expression was quantified by real time RT-PCR in HepG2-
rNtcp cells with or without transfection of rFxr- and hRXRα-expression plasmids and 
cultured in the presence or absence of chenodeoxycholic acid (CDCA) and/or 9cRA. 
BSEP promoter activity was measured by luciferase reporter assays and FXR/RXR 
DNA binding by electrophoresis mobility shift assays. Vitamin A-depleted C57BL/6J 
mice were used to evaluate the effect on cholic acid-induced Bsep and Shp expression 
in vivo. 
In vitro, 9cRA strongly antagonized the CDCA-dependent BSEP gene transcription, by 
inhibiting binding of the FXR/RXR heterodimer to the BSEP FXR response element. 
In contrast, 9cRA agonized SHP expression. In vivo, vitamin A depletion enhanced 
cholic acid-induced expression of Bsep mRNA and protein, while reducing SHP 
expression. 
9cRA either agonizes (SHP) or antagonizes (BSEP) bile acid-activated transcription of 
FXR/RXR-target genes. Vitamin A is therefore an important determinant in 
regulation of bile acid transport and synthesis. In patients with obstructive cholestasis, 
vitamin A derivatives may be therapeutically useful to decrease BSEP expression, 
thereby reducing the hepatobiliary bile acid flux and as a result reduce the pressure in 
the biliary tree. 










Vitamin A or retinol is important in a number of biological processes, including 
reproduction, embryogenesis, visual function, growth and development. All vitamin A 
present in the body is acquired from the diet. It is mainly stored in the stellate cells of 
the liver as retinyl esters that can be converted to various biological active compounds 
such as retinoic acid, all-trans retinoic acid and 9-cis retinoic acid (9cRA). 9cRA is the 
natural ligand for the retinoid X receptor or RXR (NR2B1),1,2 a ligand-activated 
transcription factor belonging to the superfamily of nuclear hormone receptors 
(NHRs). In fact, RXR is a central dimerization partner for several members of this 
superfamily, including the thyroid hormone receptor (TR), vitamin D receptor (VDR), 
peroxisome proliferator activated receptors (PPAR's), liver X receptor (LXR), 
pregnane X receptor (PXR), farnesoid X receptor (FXR) and RXR itself. The ligands 
for these receptors are metabolites or drugs that, through activation of the NHR, 
regulate the transcription of genes involved in metabolism and/or transmembrane 
transport of the ligand. The fact that these NHRs are active as heterodimers with 
RXR emphasizes the importance of vitamin A for a wide range of physiological 
processes. 
FXR is the mammalian bile acid sensor that controls bile acid homeostasis. 
Consequently, FXR is crucial for cholesterol metabolism and the intestinal uptake of 
fat-soluble vitamins. It binds and is activated by bile acids.3-5. Together with RXR, it 
directly stimulates the expression of the hepatocanalicular bile salt export pump 
(BSEP),6,7 the ileal bile acid binding protein (IBABP),8 Phospholipid Transfer Protein (PLTP, 9 
and the transcription factor Small Heterodimer Partner 1 (SHP).10 SHP represses the 
expression of cholesterol 7α-hydroxylase,11 the rate-limiting enzyme in the bile acid 
biosynthesis, and the sodium-dependent taurocholic acid cotransporting peptide (NTCP),12 the 
basolateral bile acid importer of the hepatocyte.  
9cRA may exert 3 different effects on transcriptional regulation by NHR/RXR 
heterodimers; 1) it is a prerequisite for activation but does not activate by itself (non-
permissive heterodimers) as observed for RXR/RAR;13 2) it activates transcription by 
itself and has an additive effect on the activation by the heterodimer partner’s ligand 
(permissive heterodimers; RXR/PPAR14 and RXR/LXR15) or 3) it may actually inhibit 
the transcription activation exerted by the ligand of the heterodimer partner 
(RXR/VDR).16,17 FXR/RXR has been described as a permissive heterodimer in the 
transcriptional control of I-BABP and PLTP.8,9 
In this study we show a target-gene selective effect of 9cRA on the FXR/RXR-
controlled transcription. In vitro, 9cRA strongly antagonized the bile acid-induced 
transcription of human BSEP, while enhancing the transcription of SHP. We found 
that 9cRA exerted this effect on BSEP transcription by inhibiting the binding of the 
FXR/RXR protein complex to the FXR-responsive element in the BSEP promoter 
element. We confirmed these findings in in vivo experiments using vitamin A-deficient 
mice. Cholic acid feeding of these animals resulted in significantly increased Bsep 
expression compared to vitamin A-sufficient mice, whereas Shp mRNA levels were 
highest under conditions of sufficient vitamin A. We discuss our findings in relation 










4.3 Materials and methods 
Cell culture and transfections 
Standard culture conditions for the human hepatoma cell line HepG2-rNtcp and 
derivatives have been described before.7 In some experiments, the serum 
concentration, and thereby the vitamin A/retinol concentration, in the medium was 
reduced to 1% (vol/vol) as specified in the text. HepG2-rNtcp cells were transfected 
with various combinations of plasmids (indicated in the text) as described before.7 
Eighteen hours after transfection, medium was refreshed and contained 
chenodeoxycholic acid (CDCA) and/or 9cRA in various concentrations, as described 
in the text. Cells were harvested after 24 hours for determination of luciferase activity 
and after 48 hours for total RNA isolation. HepG2-rNtcp cells stably expressing rat 
Fxr were obtained after cotransfecting these cells with pCMX-rFxr and pHMR272.18 
Hygromycin B-resistant clones were collected and rFxr-expressing cells were selected 
by RT-PCR.  
Plasmids 
Plasmids for overexpression of rat Fxr (pCMX-rFxr), human RXRα (pSG5-hRXRα), 
and the luciferase reporter vector containing the –105 to –277 base pairs BSEP 
promoter fragment (pGL3-277), control and carrier plasmids (pCMV5 and pGEM-5) 
were described before.7 
Luciferase assay 
The luciferase reporter assay to measure the BSEP promoter activity was described 
before.7 
Reverse-transcription polymerase chain reaction (RT-PCR) 
Total RNA isolation and quantitative real-time detection RT-PCR analysis of 
BSEP/Bsep, SHP/Shp, Ntcp and Rxrα mRNA levels were described before.7,19 Details 
about primer- and probe-sequences are available at the authors. 
Electrophoretic Mobility Shift Assay 
Isolation of nuclear extracts from HepG2-rNtcp cells and the protocol for the 
electrophoretic mobility shift assay have been described before.20 The FXRE probe 
contained the IR-1 sequence (underlined) from the BSEP promoter: 5’-
GATCCCTTAGGGACATTGATCCTTAGG-3’, and was labeled with [α-32P]dATP 
(Amersham, Buckinghamshire, UK) using Klenow polymerase (Promega, Madison, 
USA). 
Animals 
Pregnant (two weeks post coitum) C57BL/6J mice were obtained form Harlan 
Nederland (Horst, the Netherlands). Food and water were available ad libitum. The 
mice were housed in a temperature-controlled environment with alternating 12 hours 









light and dark cycles. Experimental protocols were approved by the Ethical 
Committee on Animal Testing of the Faculty of Medical Sciences, University of 
Groningen. 
Experimental design 
Male C57BL/6J mice were made vitamin A-deficient essentially as described by Smith, 
1990.21 In short, pregnant C57BL/6J mice received a standard laboratory chow upon 
arrival. At parturition (one week after arrival), the dams were divided into two groups 
(dam + offspring). One group received a vitamin A-deficient diet (VAD; 4148.10, 
Hope Farms, Woerden, the Netherlands) and the control group received control diet 
(4068.02, Hope Farms BV, Woerden, the Netherlands), containing 18,000 IU vitamin 
A/kg. After weaning (21-25 days), the male pups continued on the same diet as the 
mother. At the age of 13 weeks, both groups (VAD and control) were divided into 
two subgroups. Group 1 continued with the VAD diet and group 2 continued with 
the VAD diet, but now supplemented with 0.5% (wt/wt) cholic acid (CA). Group 3 
continued on the control diet and group 4 continued on the control diet, but now diet 
supplemented with 0.5% (wt/wt) CA. One week later, the mice were weighed and 
killed. The livers were removed, weighed, cut into pieces, snap-frozen in liquid 
nitrogen, and stored at -80˚C for mRNA isolation, Western blot analysis and 
immunofluorescence microscopy. Vitamin A deficiency was determined by high 
performance liquid chromatography analysis of retinol levels in fresh liver tissue 
according to Academic Hospital Groningen protocols. 
Liver plasma membrane isolation 
Total plasma membranes were isolated from 3 to 4 pooled mouse livers using sucrose-
gradient ultracentrifugation according to Meier and Boyer, 199022 with some 
modifications as described by Vos et al., 1998.23  
Western Blot analysis 
Equal amounts of liver plasma membrane proteins were separated by 7.5% SDS-
PAGE24 and analyzed for Bsep and Na+K+-ATPase protein expression by Western 
blotting.25 Polyclonal antibodies used, were raised against Na+K+-ATPase (gift from 
Dr. W. Peters, University Medical Center, Nijmegen, the Netherlands) and BSEP 
(K1223 Protein concentrations were determined using the Bio-Rad Protein Assay 
system (Bio-Rad GmbH, Munich, Germany) using bovine serum albumin as standard. 
Confocal laser scanning microscopy 
For microscopical analyses, frozen mouse liver tissue was cut into 4 µm-sections. 
After drying, the liver sections were fixed in acetone and stained for Bsep expression 
using K12, with the corresponding second antibody Alexa fluor 488 (Alexis 
Biochemicals, Lausen, Switzerland). Images were taken with a confocal laser scanning 
microscope (TCS 4D; Leica, Heidelberg, Germany) equipped with an argon/krypton 












Data are presented as means ± sd. Differences between the animal groups were 
determined in SPSS by one-way ANOVA with Scheffe as post hoc test and p<0.05. 
4.4 Results 
9-cis Retinoic acid antagonizes CDCA-induced expression of 
human BSEP in vitro 
To study the role of 9cRA in the transcriptional regulation of the human BSEP gene, 
we transfected HepG2-rNtcp cells with expression vectors for rFxr and hRXRα and 
cultured these cells in the presence of CDCA with or without various concentrations 
of 9cRA. As observed before, CDCA alone resulted in a strong (50-fold) increase of 
BSEP mRNA level (Fig. 4-1a). Surprisingly, the bile acid induction was strongly 
attenuated (to 6.0-fold compared to control cells) when also 1 μmol/L 9cRA was 
added to the culture medium. This inhibitory effect was dose-dependent, and 
disappeared when 9cRA concentrations were reduced to 10 nmol/L or lower. 
Notably, a 9cRA-dependent elevation of BSEP expression above the CDCA-induced 
levels was never observed. The 9cRA-dependent suppression of the CDCA-induced 
expression of human BSEP was also observed in untransfected HepG2-rNtcp cells 
(Fig. 4-1b). Reducing the concentration of serum, which also contains 9cRA/vitamin 
A (± 0.5 µmol retinol/L), in the culture medium to 1% strongly increased the CDCA-
induced expression of BSEP, which was suppressed after adding 9cRA to this 
medium. In HepG2-rNtcp cells stably transfected with rat Fxr, the CDCA and 9cRA 
regulated expression of endogenous BSEP was similar, but strongly amplified 






































































































































































































































Fig. 4-19cRA inhibits CDCA-stimulated BSEP mRNA expression. (a) BSEP mRNA levels in 
HepG2-rNtcp cells after transfection with the indicated expression vectors for hRXRα and/or 
rFxr, and treatment with 100 µmol/L CDCA with or without simultaneous addition of 9cRA 
in the concentration range of 1μmol/L to 1 nmol/L. BSEP (b,c) and SHP (d,e) mRNA levels 
in HepG2-rNtcp cells (b,d) or HepG2-rNtcp cells stably expressing rFxr (c,e), cultured in 10% 
(vol/vol) serum (black bars) or 1% serum (vol/vol) (white bars), and incubated with 50 
µmol/L CDCA or 1 µmol/L 9cRA as indicated. BSEP and SHP relative mRNA levels were 
determined by RT-PCR and normalized to 18S. Values are presented as mean ± sd. 
9cRA agonizes CDCA-induced expression of human SHP 
The small heterodimer partner 1 (SHP) is also a well-established FXR target gene. 
Therefore, we determined the effect of 9cRA on the CDCA-induced expression of 
SHP. In untransfected HepG2-rNtcp cells, CDCA-induced expression of SHP 2.0-
fold and 9cRA further increased this to 2.6-fold relative to control cells (Fig. 4-1d). 
The additive effect was also observed when these cells were grown in medium 
containing 1% serum and in HepG2-rNtcp cells stably expressing rFxr (Fig. 4-1e). 

































































Fig. 4-2 The CDCA-induced promoter activity of BSEP is antagonized by 9cRA. HepG2-
rNtcp cells were transfected with pGL3-277 in combination with the indicated expression 
vectors for hRXRα and/or rFxr, and were treated with 100 µmol/L CDCA with or without 
simultaneous addition of various concentrations of 9cRA (indicated as mol/L). After 24 hours, 
cells were harvested and luciferase activities were determined. Values are presented as mean ± 
sd. 
9cRA reduces the CDCA-induced BSEP promoter activity 
Luciferase reporter gene assays were performed to determine whether 9cRA acts 
directly on the BSEP promoter activity. HepG2-rNtcp cells were transfected with 
pGL3-277, containing the minimal BSEP promoter sequence including the FXR 
responsive element (FXRE), in combination with rFxr and hRXRα expression 
plasmids. When grown in the absence of CDCA and 9cRA, these cells showed 
significant levels of luciferase activity (69-fold induced compared to pGL3-227 alone), 
probably due to stimulation of the rFxr/hRXRα by bile acids produced by HepG2 
cells.26,27. Luciferase activity was, however, super-induced by the addition of CDCA to 
the medium (134-fold). As observed with the endogenous BSEP mRNA levels, 1 
μmol/L 9cRA fully inhibited the CDCA-induced luciferase activity and this effect was 
also dose-dependent (Fig. 4-2). 
9cRA reduces FXR/RXR binding to the BSEP-FXR responsive 
element 
Next, we studied whether 9cRA caused changes in the binding of the FXR/RXR 
heterodimer to the FXRE in the BSEP promoter. An electrophoretic mobility shift 
assay was performed using the human BSEP FXRE sequence and nuclear extracts 









from HepG2-rNtcp cells cultured in the absence or presence of CDCA and 9cRA. In 
control cells (Fig. 4-3, lanes 1 and 2) and cells treated with CDCA, a clear band 
representing the FXR/RXR heterodimer was observed (Fig. 4-3, lane 3 and 4). In cells 
treated with CDCA and 9cRA this band is absent (Fig. 4-3, lanes 5 and 6), showing 
that 9cRA reduces binding of the endogenous human FXR/RXR heterodimer to the 

























Fig. 4-3 FXR/RXR binding to the BSEP-FXRE oligonucleotide is lost upon 9cRA treatment. 
HepG2-rNtcp cells were incubated with vehicle (lanes 1 and 2), with 100 µmol/L CDCA 
(lanes 3 and 4), or with 100 µmol/L CDCA and 1 μmol/L 9cRA (lanes 5 and 6). Nuclear 
extracts were obtained and an electromobility shift assay was performed using the radioactively 
labeled FXRE from the BSEP promoter. 
Vitamin A deficiency increases cholic acid-induced Bsep 
expression in vivo 
To establish the role of vitamin A, and its derivative 9cRA, in regulating BSEP levels 
in vivo, we analyzed the effect of cholic acid-feeding in normal and vitamin A-deficient 
mice. From birth, male C57BL/6J mice were either fed a vitamin A-sufficient 
(control) or a vitamin A-deficient (VAD) diet. At 13 weeks of age, both groups were 
subdivided in two: one group continued on the same diet, while in the other group the 
diet was supplemented with 0.5% (wt/wt) CA. One week later, the mice were killed 










Survival of control mice was 100%, while the survival of the VAD mice was 50% 
(without CA) and 54% (with CA) (Table 4-1). The survivors in the VAD groups 
appeared healthy and showed no apparent symptoms of deficiency.  
Retinol levels were undetectable in the livers (Table 4-1) and serum (data not shown) 
from VAD mice, whereas they were readily detectable in mice on control diets. No 
statistically significant differences were observed between control and VAD mice for 
general parameters, like body weight, liver weight, and liver to body ratio (Table 4-1), 
except for the mean body weight of the VAD group (p = 0.03 versus control) and the 
VAD with CA diet group (p = 0.012 versus VAD). The plasma bile salts of the VAD 
with CA diet group was significantly different compared to the control group (p = 





Mean ± sd 
Control+CA 
n=7 
Mean ± sd 
VAD 
n=12 
Mean ± sd 
VAD+CA 
n=13 
Mean ± sd 
Body weight (g) 26.9±1.1 25.8±.6 22.9±2.8a 26.6±1.1c 
Liver weight (g) 1.0±0.2 1.2±0.1 1.0±0.2 1.1±0.2 
Liver to body ratio 0.037±0.006 0.045±0.003 0.044±0.005 0.042±0.007 
Plasma bile salts (μmol/L) 36.5±6.9 62.3±10.8 40.3±7.9 76.4±34.1ac 
Survival (%) 100 100 50 54 
Liver vitamin A (μmol/g) 93.6±33.8 135.9±34.2 n.d. n.d. 
Table 4-1 Animal characteristics, hepatic vitamin A level and survival percentage in male 
C57BL/6J mice, either fed the control or VAD diet, with or without 0.5% (wt/wt) CA 
supplementation. Data are presented as mean ± sd. (a: significantly different from control 
group; c: significantly different from VAD group; n.d.: not detectable) 
 
Hepatic Bsep, Shp, Ntcp and Rxrα mRNA expression was determined by quantitative 
real-time RT-PCR (Fig. 4-4) and Northern blot analysis (Bsep, data not shown). Both 
methods revealed that CA-feeding of VAD mice resulted in highest Bsep mRNA levels 
(3.4-fold increased compared to control (p < 0.001) whereas it led to only a 1.7-fold 
increase in mice on control diets (Fig. 4-4a). Bsep mRNA levels were not increased in 
mice receiving the VAD diet without CA. In contrast, Shp levels were highest in cholic 
acid-fed control mice (2.2-fold increase compared to control), slightly reduced in 
VAD mice (0.7-fold) but still inducible by CA-feeding (1.7-fold) (Fig. 4-4b). This was 
also reflected in the Ntcp mRNA levels that were lowest in CA-fed control mice (0.3-
fold, p = 0.007 versus control) and not significantly changed in VAD mice (Fig. 4-4c). 
Importantly, Rxrα expression was similar in all 4 groups, with only a slight, although 
significant, increase in the VAD+CA group (1.5-fold increase compared to control, p 
= 0.007, Fig. 4-4d). 



















































































































































Fig. 4-4 Bsep mRNA expression is significantly increased by cholic acid-feeding in VAD mice, 
but not in control mice. Total RNA was isolated from liver sections of mice either fed the 
control diet (black bars) or VAD diet (white bars), with (+) or without (-) 0.5% (wt/wt) CA 
supplementation. Relative Bsep (a), Shp (b), Ntcp (c) and Rxrα (d) mRNA levels normalized to 
18S were analyzed by RT-PCR. Data are presented as mean ± sd of individual mice per group. 
(a: significantly different from control group; b: significantly different from control+CA group; 
c: significantly different from VAD group; d: significantly different from VAD+CA group) 
 
The difference in Bsep mRNA levels was also reflected in the Bsep protein level in 
liver membrane fractions (Fig. 4-5). As shown for the Bsep mRNA, CA-feeding in 
control mice and vitamin A deficiency by itself did not result in altered Bsep protein 
levels (Fig. 4-5). In contrast, Bsep protein levels were significantly increased in VAD 
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Fig. 4-5 Bsep protein expression is increased by cholic acid-feeding in VAD mice, but not in 
control mice. Liver plasma membranes were isolated from pools of 3 to 4 livers from mice 
either fed the control of VAD, supplemented with (+) or without (-) 0.5% (wt/wt) CA. Equal 
amounts of two independent membrane isolations were subjected to Western blot analysis, and 










Immunofluorescence microscopical analyses of liver sections revealed a normal 
canalicular staining for Bsep for mice from all 4 groups, indicating that the VAD diet 





Fig. 4-6 Bsep protein expression shows a normal canalicular staining pattern in VAD mice. 
Liver sections from mice, fed the control diet (a), control diet supplemented with 0.5% 
(wt/wt) CA (b), VAD diet (c) or VAD diet supplemented with 0.5% (wt/wt) CA (d), were 
stained for Bsep. The protein expression pattern was analyzed using confocal laser scanning 
microscopy. 
4.5 Discussion 
In this study, we show that vitamin A and its derivative 9cRA play an important role 
in the transcriptional regulation of genes controlling bile acid homeostasis. In vitro, 
9cRA antagonized the bile acid-induced expression of BSEP by the FXR/RXR 
heterodimer, while it agonized SHP expression. In vivo, vitamin A deficiency strongly 
increased the bile acid-induced Bsep mRNA and protein levels in CA-fed mice. 
BSEP is specifically expressed in the liver and transports bile acids across the 
canalicular membrane.28 It plays a crucial role in the enterohepatic circulation of bile 
acids.29,30. Previous studies have shown that BSEP gene transcription is controlled by 
its substrates, mediated through the bile acid sensor FXR and its heterodimer partner, 
RXR.6,7. Other FXR/RXR target genes include SHP,10 IBABP,8 PLTP,9 
Dehydroepiandrosterone Sulfotransferase,31 Apolipoprotein C-II,32 Multidrug Resistance-Associated 
Protein 2,33 Organic Anion Transporting Polypeptide 8,34 Kininogen,35 Bile acid-CoA synthetase 
and Bile acid-CoA: amino acid N-acetyltransferase.36 Expression analyses on IBABP and 
PLTP have shown that maximal FXR/RXR transcriptional activation was observed 
when both FXR- (CDCA) and RXR- (9cRA) ligands were present.8,9 This study 









revealed similar results for SHP, but the opposite effect was observed for BSEP. 
9cRA strongly attenuated the bile acid-induced BSEP transcription by FXR/RXR. 
One other example of an inhibitory effect of 9cRA on an RXR/NHR heterodimer 
has been described and studied in detail. In concert with RXR, the vitamin D receptor 
(VDR) regulates the transcription of genes involved in calcium and phosphate 
homeostasis.37 Transcription of the rat osteocalcin gene was found to be activated by 
VDR, RXR and the VDR-ligand 1,25-dihydroxyvitamin D3, but inhibited by 9cRA, 
which destabilized the DNA bound RXR/VDR heterodimer.16 Similarly, we found 
that the presence of 9cRA resulted in a decreased formation of the FXR/RXR-DNA 
complex as shown by electrophoretic mobility shift assay analysis. Our data are in line 
with the recent report by Kassam et al.,38 who showed that the RXR ligands 
LG100268 and 9cRA inhibit the binding of in vitro translated FXR and RXR to the 
BSEP-FXRE. In addition, we show that 9cRA is required for maximal CDCA-
induced expression of SHP. The molecular basis for the variable effect of 9cRA on 
FXR/RXR target genes is still unclear, but may be caused by differences in or close to 
the FXRE in the corresponding promoter elements or the selective interaction with 
transcription coactivators.38 
The crucial question we wanted to address in this study was: does vitamin A play a 
role in BSEP expression in vivo? From the in vitro data we hypothesized that 
physiological levels of vitamin A may actually reduce bile acid-induced expression of 
Bsep in mice with a normal vitamin A status. In line with this, Wolters et al.39 reported 
only minor effects on Bsep expression after taurocholic acid-feeding of wild type 
mice. Therefore, we fed C57BL/6J mice a vitamin A-deficient diet and analyzed its 
effect on mRNA levels of the Fxr-target genes Bsep and Shp. Vitamin A deficiency in 
mice strongly increased bile acid-dependent Bsep expression, whereas it reduced Shp 
expression, confirming our in vitro results using human HepG2 cells. 
These data may have important implications for therapeutic interventions aimed at 
regulating canalicular bile acid secretion in cholestatic patients. Chronic liver disease, 
in particular chronic cholestatic liver disease, leads to vitamin A deficiency.40,41 
However, vitamin A supplementation in liver disease is a controversial issue.42 Our 
data may explain this phenomenon. In chronic cholestatic liver disease, the increased 
intrahepatocellular bile acid concentration, in combination with a decreased vitamin A 
concentration, presents the optimal condition for BSEP induction. NTCP, however, 
remains expressed because of a lack of induction of SHP, the negative regulator of 
NTCP. Thus the hepatobiliary secretion of bile acids remains intact to some extend. 
Supplementation with vitamin A would, in theory, aggravate the cholestasis in these 
patients: it would reduce BSEP expression, activate SHP and thereby reduce NTCP 
expression. When viewed from the hepatocyte, vitamin A has a cytoprotective effect. 
However, in case of extrahepatic bile duct obstruction, persistent or elevated BSEP 
activity may contribute to increase intraluminal pressure in the intrahepatic 
cholangioles. This may result in bile infarcts and cause considerable damage of the 
liver parenchyma.43 Ursodeoxycholic acid therapy may be harmful for these patients, 
since it further increases biliary pressure. Reducing BSEP expression through vitamin 
A supplementation may protect the liver in this case. Support for this hypothesis was 










combination with biliary obstruction results in a significant reduction of liver 
fibrosis.44 
In conclusion, it is evident that vitamin A plays a crucial, but complex role in the 
physiological processes regulated by the nuclear hormone receptors. Vitamin A is 
required for optimal activation of RXR/RAR-, RXR/TR-, RXR/LXR- and 
RXR/PPAR-target genes. In contrast, high levels of vitamin A attenuate, and low 
levels stimulate, bile acid-induced transcription of BSEP. These observations show 
that 9cRA is an important molecular switch and that its effect needs to be determined 
for every individual RXR/NHR target gene and cannot be extrapolated from data 
obtained from studies on other target genes. Finally, the clinical role of vitamin A 
repletion in chronic liver disease needs to be redefined. 
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Bile salts act as detergents and keep hydrophobic compounds in solution in the 
gastrointestinal tract. They are also potent regulators of gene transcription. They bind 
and activate the Farnesoid X Receptor (FXR), which regulates transcription of genes 
encoding enzymes and transmembrane transporters involved in bile salt and 
cholesterol metabolism. FXR is also known to regulate bile salt/cholesterol-unrelated 
genes. In this study, we performed a transcriptome analysis to determine the genome-
wide effect of FXR-activation and to identify possible new FXR target genes. 
Native and ratFxr-overexpressing HepG2-rNtcp cells were cultured in the absence or 
presence of the bile salt chenodeoxycholic acid. Changes in mRNA levels were 
analyzed using microarrays and real time RT-PCR. 
Besides known non-bile salt/cholesterol-related FXR-target genes like kininogen, 
apolipoprotein AV, apoliprotein C-II and SLC21A88, Fibrinogen Bβ was identified as a 
novel gene positively regulated by FXR and chenodeoxycholic acid. Analysis of the 5’ 
regions of the human, mouse, and rat Fibrinogen Bβ gene revealed a highly conserved 
inverted repeat element separated by 9 nucleotides that might be involved in the FXR-
dependent regulation. 
In conclusion, this study reveals a novel, positively regulated FXR-target gene, 
Fibrinogen Bβ, which encodes for a plasma glycoprotein that is involved in blood 
clotting. 










Bile salts are the main solutes in bile and function as stimulators of fat digestion. They 
also facilitate the biliary secretion of hydrophobic compounds such as cholesterol en 
toxins. In recent years, bile salts have been shown to perform many other 
physiological functions. For example, they are mediators of apoptosis,1 activators of 
protein kinase C2 and phosphatidylinositol-3 kinase.3 Most importantly, bile salts play 
a crucial role as regulators of gene transcription, by means of binding and activation of 
the transcription factor, farnesoid X receptor (FXR).4,5 
FXR belongs to the nuclear hormone receptor superfamily of ligand-regulated 
transcription factors. It is active as a heterodimer with the retinoic acid receptor 
(RXRα).6 RXRα is activated by the vitamin A derivative 9-cis retinoic acid.7 The 
activated FXR/RXR heterodimer binds to a specific DNA sequence, the FXR 
responsive element (FXRE), in the promoter region of target genes. This FXRE 
consists of an inverted repeat element of two 6 base pair motif, AGGTCA, with a 1-
base pair spacing (IR-).6,8 
FXR was first identified as a receptor for farnesol metabolites, and is expressed in 
liver, gut, adrenal gland and kidney.6 Recent data show that this nuclear receptor is the 
mammalian bile salt sensor that plays an important role in maintaining bile salt and 
cholesterol homeostasis. In accordance with this role, several FXR-target genes have 
been identified that are involved in bile salt and cholesterol metabolism. These include 
(1) the bile salt export pump (BSEP, ABCB11),9 the major hepatic bile salt exporter;10 (2) 
the intestinal bile acid-binding protein,11 which is an intestinal protein that binds bile salts 
with high affinity in the cytosol of enterocytes and (3) the transcription factor small 
heterodimer partner 1.12 Small heterodimer partner 1 in its turn  represses transcription of 
cytochrome P450 7a1,12 the rate-limiting enzyme of bile salt synthesis and the sodium-
dependent taurocholate cotransporting protein (Ntcp), the major hepatic bile salt importer. 
apolipoprotein A-1 and the phospholipid transfer protein are both involved in HDL-
cholesterol metabolism and are also regulated by FXR.13,14. 
Recent studies have shown that FXR is also involved in the transcription of non-bile 
salt and cholesterol-related genes. These include apolipoprotein AV15 and apoliprotein C-
II,16 which are both involved in triglyceride metabolism. Also the organic anion 
transporting polypeptide 8 (OATP8 or SLC21A8),17 transporter of organic anions and 
xenobiotics, and Kininogen (KNG),18 which is involved in anti-coagulation fall into this 
latter category. KNG transcription shows the most pronounced response to CDCA-
activated FXR of all FXR-target genes studied thus far. 
In the present study, we performed a transcriptome analysis on human HepG2 cells 
stably expressing rat Fxr to determine the effect of activated Fxr on approximately 
18,000 human genes with known functions. In addition to the known FXR target 
genes indicated above, we show that also Fibrinogen Bβ (FGB) gene transcription is 
positively regulated by bile salts and FXR. The genes for human, rat and mouse FGB 
contain a sequence in their promoter elements that closely resembles a FXRE. 
However, in contrast to the IR-1, the inverted repeat sequences in the FGB promoter 
elements are separated by 9 nucleotides. This IR-9 sequence might be a novel FXRE 










increasing number of genes unrelated to bile salt or cholesterol metabolism that are 
regulated by FXR. Since FXR is considered a drug target for the treatment of 
cholestatic conditions, possible unwanted effects may result from the changed 
expression of these other FXR-target genes. 
5.3 Materials and methods 
Cell culture 
The stably transfected human hepatoma cell line HepG2, expressing the rat sodium-
dependent taurocholate cotransporting protein (HepG2-rNtcp)19 were cultured at 
37°C in a humidified atmosphere of 5% CO2 in air, in DMEM with GlutaMAX-1, 
4500 mg/L D-glucose, sodium pyruvate, pyridoxine supplemented with 10% 
(vol/vol) heat-inactivated FBS, 100 U/ml penicillin G, 100 µg/ml streptomycin, 250 
ng/ml fungizone and 250 µg/ml geneticin (Invitrogen BV, Breda, The Netherlands). 
The cell culture was passed twice a week. 
Stable transfection 
Plasmid DNA was isolated and purified using the EndoFree® Plasmid Maxi Kit 
(QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s instructions. 
HepG2-rNtcp cells 19 were transfected by the calcium phosphate co-precipitation 
method20 using an expression vector for rat Fxr, pCMXrFxr and the hygromycin B-
selection plasmid, pHMR272.21 Upon selection on hygromycin B-resistance, the rFxr-
expressing cells were further cultured in normal HepG2-rNtcp medium. 
Microarray 
For the microarray analysis, HepG2-rNtcp and HepG2-rNtcp-rFxr cells were cultured 
in the presence or absence of 100 µmol/L CDCA (sodium salt, Calbiochem-
Novabiochem, San Diego, CA) dissolved in phosphate-buffered saline (PBS) for three 
days. Total RNA was isolated as described22 and labeled using the Agilent Fluorescent 
Direct Label Kit according to the manufacturer’s instructions (Agilent Technologies, 
Palo Alto, CA). The control samples (HepG2-rNtcp+PBS) were labeled with 
Cyanine-5 and the experimental samples (HepG2-rNtcp+CDCA and HepG2-rNtcp-
rFxr + CDCA) were labeled with Cyanine-3. The labeled cDNA’s were hybridized on 
Human 1A Oligo Arrays, using the Agilent Oligonucleotide Microarray Hybridization 
Kit (Agilent Technologies, Palo Alto, CA). The experiment was done in duplo. The 
arrays were collected and analyzed using the Agilent Microarray Scanner System and 
Feature Extraction Software (Agilent Technologies, Palo Alto, CA). Genes meeting 
the criteria (average of cyanine-3 and cyanine-5 normalized signals > 8 and P-value of 
the Log Ratio < 0.01) were used for further analysis. 
Reverse-transcription polymerase chain reaction (RT-PCR) 
Total RNA isolation and quantitative real-time detection RT-PCR analysis of 
BSEP/Bsep, FGB/Fgb, SLC21A8, and KNG mRNA levels were described before.22,23 
Details about primer- and probe-sequences are available at the authors. 










Male C57BL/6J mice (Harlan Nederland, Horst, the Netherlands) were housed in a 
temperature-controlled environment with alternating 12 hours light and dark cycles. 
Food and water were available ad libitum. Experimental protocols were approved by 
the Ethical Committee on Animal Testing of the Faculty of Medical Sciences, 
University of Groningen. 
Experimental design  
At the age of 13 weeks, the mice were divided into groups. Group 1 continued with 
their normal diet, while group 2 received their diet supplemented with 0.5% (wt/wt) 
cholic acid (CA). One week later, the mice were weighed and killed. The livers were 
removed, weighed, cut into pieces, snap-frozen in liquid nitrogen, and stored at -80˚C 
for mRNA isolation. 
Statistic 
Data are presented as means ± sd. Differences between the two animal groups were 
determined in SPSS by a Mann-Whitney U-test and p<0.05. 
5.4 Results 
Generation of rFxr-expressing HepG2-rNtcp cells 
FXR is a potent regulator of transcription of genes involved in bile salt and 
cholesterol metabolism. As such, it is regarded an important target for controlling bile 












































Fig. 5-1 CDCA-induced BSEP expression is strongly increased in HepG2-rNtcp cells stably 
transfected with rat Fxr. HepG2-rNtcp cells were incubated with vehicle (PBS, black bar) or 
100 µM CDCA (gray bar) and HepG2-rNtcp-rFxr cells were incubated with 100 µM CDCA 
(white bar). Total RNA was isolated and BSEP mRNA levels were determined by real time 










In recent years, novel FXR-target genes have been identified that are not involved in 
bile salt/cholesterol metabolism. These genes may cause unwanted or unexpected side 
effects during FXR-targeted therapy. We therefore determined the effect of activated 
FXR on the transcription of approximately 18,000 human genes with the aim to 
characterize FXR-controlled processes unrelated to bile salt/cholesterol homeostasis. 
We generated HepG2-rNtcp cells that stably express rat Fxr for the identification of 
new FXR- and CDCA-regulated genes. BSEP mRNA expression served as a positive 
control for the functionality of rFxr in this cell line. Both native and rFxr-expressing 
cells were treated with 100 µM CDCA and compared to the native cells treated with 
vehicle. As expected, BSEP expression was significantly increased by both CDCA and 
rFxr, showing 7-fold increased mRNA levels in CDCA-treated HepG2-rNtcp and a 
68-fold increase in CDCA-treated HepG2-rNtcp-rFxr cells, respectively, compared to 
HepG2-rNtcp cells grown in the absence of CDCA (Fig. 5-1). 
Selection of significant up-regulation or down-regulation of genes 
in microarray 
Next, the same cDNA samples were analyzed using the Agilent Human 1A Oligo 
Arrays to identify novel FXR target genes. Four individual microarray hybridization 
experiments were performed. cDNA from control cells (group C) were labeled with 
Cy5 and used as control in all 4 experiments. cDNA from CDCA-treated HepG2-
rNtcp (CDCA) or HepG2-rNtcp-rFxr (FXR/CDCA) cells were labeled with Cy3. 
Two arrays were hybridized with the combination C versus CDCA (chip 1a and b). 
The other two with the combination C versus FXR/CDCA (chip 2a and b). The 
rational behind this setup was that possible rFxr-unrelated CDCA effects on 
transcription could be excluded, and that limited regulation of FXR-target genes 
would be strongly enhanced in the rFxr-transfected cells. Criteria were set to evaluate 
the significance of changed expression levels under the 3 different conditions. These 
parameters were: (1) The CDCA-induced expression (C versus CDCA) should be at 
least 1.5; (2) the average of both (Cy3 and Cy5) normalized (log) signal intensities 
should be > 8. This limit is arbitrary and signals with an intensity of ≤ 8 are assumed 
to be unreliable; (3) the P value for significance was < 0.01. Four hundred thirty five 
(435) transcripts met these criteria on both a and b chips and were included for the 
final analysis: The rFxr-induced expression (CDCA versus FXR/CDCA) should be at 
least 1.2. 
Positively regulated genes by CDCA-activated rFxr 
BSEP expression, though used to validate our experimental setup (Fig. 5-1), did not 
meet the microarray analysis parameters. This was, however, not unexpected since 
HepG2 cells are well known to express BSEP only at very low levels.22 Even the 68-
fold increase of BSEP in the CDCA-treated HepG2-rNtcp-rFxr cells remained below 
the detection limits of the microarray 2. Two other established FXR-target genes, 
SLC21A817) and KNG,18 were expressed to significant levels and were selected to 
determine their expression differences between the two arrays (bold in Table 5-1). 
KNG shows the strongest relative increase to CDCA-treatment, i.e. 5.5-fold in 









HepG2-rNtcp cells and 7.9-fold in HepG2-rNtcp-rFxr cells. SLC21A8 mRNA 
expression levels were 2.2-fold increased in HepG2-rNtcp cells and 3.0-fold in 
HepG2-rNtcp-rFxr cells. The additive effect of rFxr for both SLC21A88 and KNG, is 








CDCA vs. FXR/CDCA 
 
FGB 2.68±0.87 5.72±2.02 2.1 
KNG 5.49±2.06 7.91±2.50 1.4 
FGG 1.99±0.22 2.79±0.49 1.4 
SLC21A8 2.16±0.33 2.98±0.78 1.4 
SURF6 2.07±0.79 2.77±0.16 1.3 
FGA 1.41 1.87±0.29 1.3 
FLJ20671 2.31±0.02 3.01±0.05 1.3 
LOC89953 3.70±0.97 4.77±0.92 1.3 
RCN1 1.57±0.24 1.98±0.15 1.3 
TMOD4 3.14±0.92 3.87±0.53 1.2 
I_1152006 2.91±0.06 3.56±0.04 1.2 
CAPN5 3.10±0.42 3.77±0.17 1.2 
PPAP2A 3.33±0.54 4.05±0.26 1.2 
Table 5-1: List of human genes of which the expression is increased at least 1.2-fold by CDCA 
and rFxr in HepG2-Ntcp cells. Agilent Human 1A Oligo arrays were hybridized with cDNA 
obtained from HepG2-rNtcp cells and HepG2-rNtcp-rFxr cells treated with CDCA (CDCA 
and FXR/CDCA respectively). The mRNA expression levels of both CDCA-treated cell lines 
were compared to those in HepG2-rNtcp cells treated with the vehicle, PBS (group C). Only 
the genes that meet the criteria as described in experimental procedures were analyzed for the 
effect of the presence of rFxr. Note: mRNA expression levels for FGA in CDCA column did 
not meet all criteria, but are included for comparison to FGB and FGG. 
 
To more accurately quantify the relative increase caused by CDCA and rFxr 
separately, RT-PCR was performed for SLC21A8 (Fig. 5-2a) and KNG (Fig. 5-2b). In 
CDCA-treated HepG2-rNtcp cells, the SLC21A8 and KNG mRNA levels were 
increased with 4.9-fold and 20.6-fold, respectively. These values further increased to 
10.2-fold and 33.7-fold, respectively, in the CDCA-treated HepG2-rNtcp-rFxr cells. 
According to this analysis the rFxr-specific effect for SLC21A8 is 2.0-fold and for 








































































































































Fig. 5-2 Human FGB expression is increased by CDCA and rFxr in HepG2-Ntcp cells. 
HepG2-rNtcp cells were incubated with vehicle (PBS, black bar) or 100 µM CDCA (gray bar) 
and HepG2-rNtcp-rFxr cells were incubated with 100 µM CDCA (white bar). Total RNA was 
isolated and SLC21A8 (a), KNG (b), and FGB (c) mRNA levels were determined by real time 
RT-PCR. The level of 18S was determined as control. 
Human Fibrinogen Bβ is a putative FXR-target gene 
Table 5-1 shows that only few additional genes confirmed to our set criteria of 1.5-
fold up-regulation upon CDCA-treatment of HepG2-rNtcp cells and a further 
significant increase of at least 1.2-fold in CDCA-treated HepG2-rNtcp-rFxr cells. The 
most eye-catching genes from this shortlist are that of Fibrinogen Aα, Bβ and gamma 
(FGA, FGB and FGG). Together, these genes encode the plasmaprotein Fibrinogen. 
The FGB gene shows the strongest response to rFxr from all detected genes in the 
microarray experiment. The FGB mRNA was increased 2.7-fold and 5.7-fold in 
CDCA-treated HepG2-Ntcp and HepG2-Ntcp-Fxr cells, respectively. Thus, the rFxr-
effect for FGB amounts to 2.1-fold. Though significantly below the 9.7-fold observed 
for BSEP by RT-PCR, it tops all genes detected in the microarray experiment, 
including KNG and SLC21A88. The rFxr-effect was confirmed by RT-PCR analysis 









for FGB, in which a 2.7-fold and 6.0-fold increase was detected in CDCA-treated 
HepG2-Ntcp and HepG2-Ntcp-Fxr cells, respectively. In addition, the expression of 
FGA and FGG was also significantly increased by CDCA and rFxr (Table 5-1). For 
FGG the CDCA-effect was 2.0-fold and the additional rFxr-effect 1.4-fold. Although 
FGA (in italic in table 5-1) did not meet our preset criterion of 1.5 (the CDCA-effect 
was just 1.4-fold), we added this gene to the list of up-regulated genes, because of its 
relation to FGB The additional rFxr effect for FGA was 1.3-fold.. Thus, all three 
genes encoding the 3 subunits of Fibrinogen show enhanced expression upon CDCA-
activation of rFxr in HepG2-Ntcp cells. 
Fibrinogen Bβ mRNA expression in cholate-fed mice 
To determine whether FXR-controlled expression of FGB also occurs in vivo we 
studied hepatic expression in mice fed a bile salt-containing diet and compared these 
to mice fed normal chow. Male C57BL/6J mice were fed a 0.5% cholate diet during 
one week. Total RNA from the livers was isolated and Fgb and Bsep mRNA expression 
levels were quantified using RT-PCR (Fig. 5-3). The Fgb mRNA level was 1.3-fold (p 
= 0.073) increased in cholate-fed animals compared to control mice, whereas Bsep 





























Fig. 5-3 The effect of cholate-feeding on hepatic Fgb expression in mouse. C57BL/6J mice 
were fed either a control diet (black bars) or a 0.5% CA-supplemented diet (white bar) for one 
week. Total RNA was isolated from their livers and Bsep and Fgb mRNA levels were 
determined by real time RT-PCR. The level of 18S was determined as control. Data are 
presented as mean ± sd. (*: significantly different from control diet, p < 0.05) 
Identification of a putative FXRE in the human Fibrinogen Bβ 
promoter region 
The positive regulation of the FGB gene by CDCA and rFxr suggest that FXR is 
directly involved in the regulation of this gene. This implies that FXR binds the FGB 
promoter element. Concurrently, we screened the FGB promoter region from human 
(gi:31400), mouse (gi:38077445) and rat (gi:204100) for candidate FXRE’s. All three 
sequences show a high degree of identity/similarity in the region immediately 
upstream of the transcription start site (Fig. 5-4). In this region we identified a highly 










the transcription initiation site), which may function as an FXRE. In human and rat, it 
consists of a perfect inverted repeat of two 6 base pair-motifs, GGTTCA and 
GTAACC, which are separated by 9 nucleotides (which would than be a IR-9). In the 
5’-flanking region of the mouse Fgb gene, there is one nucleotide difference compared 
to the human and rat sequence; AGTTCA and TGAACC. 
 




***** ***  ******************* **********   ***********************        
HNF1                                                    TATA-box       
-88 TTAAATATTAACTAAGGAAAGGTAACCATTTCTGAAGTCATTCCTAGCAGAGGACTCAGATATATATAGG  -19
-87 TCAAATATTAACTAAAGGGAGGTAACCATTCCTGAAGTCATGCCGGGGAGAGGAC-CCACTATATATAGG  -19
-87 TCAAATATTAACTAAAGGGAGGTAACCATTCCTGAAGCCATGCCCGTGAAAGGAC-CCGTTATATATAGG  -19
* ************* *  *********** ****** *** **    * ***** *  **********     
Ð
-18 ATTGAAGATCTCTCAGTTAAGTCTACATGAAAAGG +17 human                              
-18 ATCGACAGTCTCCCAGCTAAGTCTACAGGCAAAGG +17 mouse                              
-18 ATCGACAGTCTCCCAGCTAGGTCTGCAGGCAAAGG +17 rat   
** **   **** *** ** **** ** * *****                        
 
Fig. 5-4 The promoter region of mammalian FGB genes contain a putative FXRE. Sequences 
of the 5’-flanking regions of the human, mouse, and rat FGB genes are shown. The conserved 
nucleotides are indicated by *. The site of transcription initiation is designated as +1 (Ð). The 
regulatory sequences IL-6RE, C/EBP, HNF1, and TATA-box, established by previous studies, 
are underlined. The proposed IR-9 is boxed, the inverted repeat element is shown in bold. 
5.5 Discussion 
In this study we show that Farnesoid X receptor (FXR) directly regulates the 
transcription of genes encoding human Fibrinogen. This is another example of FXR 
regulating the transcription of genes that appear unrelated to bile salt and/or 
cholesterol homeostasis. These effects need to be considered in future therapies 
aiming at manipulating bile salt and/or cholesterol levels through FXR. 
FXR is generally viewed as the bile salt sensor that regulates transcription of key genes 
involved in bile salt homeostasis. It may activate transcription of target genes directly 
after binding to FXR-response elements in their promoter region, or repress 
transcription indirectly through up-regulation of the transcriptional repressor, small 
heterodimer partner (SHP-1). Genes involved in bile salt homeostasis that are directly 
or indirectly regulated by FXR include the ones for the rate-limiting enzyme in bile 
salt biosynthesis, cytochrome p450 7a1, the hepatic bile salt transporters Ntcp (uptake) 
and BSEP (secretion), and intestinal bile acid binding protein. It is therefore an important 
pharmacological target to control the enterohepatic circulation of bile salts. Recent 
studies have shown that FXR also directly regulates genes that are not linked to bile 
salt and cholesterol metabolism. We performed microarray analyses to reveal more of 
these non-bile salt and cholesterol related genes as targets for FXR. HepG2-rNtcp 
cells and their rat Fxr-expressing derivatives, the HepG2-rNtcp-rFxr cells, were 









treated with CDCA. This treatment resulted in increased mRNA expression levels of 
already established FXR-regulated genes, like SLC21A8 and KNG. BSEP expression 
remained undetectable in the microarray experiments, even though its expression is 
68-fold increased in the CDCA treated HepG2-rNtcp-rFxr cells. BSEP expression is 
known to be low in HepG2 cells. The limited sensitivity of microarray experiments is 
clearly a drawback of this technique and biases the results towards highly expressed 
genes. Physiological important FXR-target genes may therefore escape identification 
using immortalized cells like HepG2 that show strongly reduced basal mRNA levels 
of subsets of genes, including BSEP and NTCP. However their accessibility towards 
genetic manipulation, here stable rFxr-overexpression, does result in relevant data 
about genes that are (still) expressed at detectable levels in such cells.  
The gene that showed the highest increase upon FXR-activation was Fibrinogen Bβ 
(FGB). FGB is a subunit of Fibrinogen that in addition consists of Fibrinogen Aα 
(FGA) and γ (FGG). Fibrinogen is a plasma glycoprotein synthesized in the liver and 
plays a role in blood clotting. The FGA, FGB and FGG genes are located in a cluster 
on chromosome 4.24 Upon vascular injury, it is cleaved by thrombin to form fibrin. 
This is achieved by coordinate transcriptional regulation of all three genes, in which 
interleukin-6 (IL-6) plays an important role.25 In addition, several cleavage products of 
fibrinogen and fibrin are involved in cell adhesion, vasoconstriction, chemotactic and 
mitogenic activities.26 The promoter regions of the human, mouse and rat FGB genes 
are highly conserved between position –157 and position +17 relative to 
transcriptional start site. Previous studies have shown that several regulatory elements 
are located within this region.27 For example, the relevance of an IL-6 responsive 
element, a C/EBP motif and an HNF-1 binding site has been demonstrated.28-30 Our 
analysis of this region revealed a highly conserved and new element between 
nucleotides –94 and –74. This element consists of a perfect inverted repeat separated 
by 9 base pairs (GGTTCA-N9-GTAACC). We hypothesize that this inverted repeat 
may be a novel FXR responsive element. The consensus FXRE is an inverted repeat 
of the AGGTCA motif with a 1 base pair spacing (IR-1). However, many exceptions 
on this consensus have been described that also bind FXR, resulting in increased 
transcription of the downstream gene. The rat dehydroepiandrosterone sulfotransferase 
promoter contains an inverted repeat with no spacing (IR-031), the human multidrug 
resistance-related protein 2 promoter contains an everted repeat with a 8 base pair spacing 
(ER-832), and human apolipoprotein-AV contains an inverted repeat with an 8 base pair 
spacing.15 Since the IR-9 in the FGB promoter is conserved between species, we 
consider this sequence as a putative FXRE. A previous study already identified the 
positions –94 and –93 in the human FGB promoter as a positive cis-acting element.30 
The IR-9 is present in the 5’-flanking region of both rat and mouse Fgb. Therefore, we 
performed experiments with freshly isolated primary rat hepatocytes, exposed them to 
CDCA and determined the effect of Fgb gene transcription. Unfortunately, Fgb 
mRNA levels strongly increase during the isolation procedure of hepatocytes, which 
returns to basal levels only 2 to 3 days after seeding the cells. During this period, 
expression of the bile salt uptake transporter, Ntcp, is reduced to below 10% of its 
normal level in hepatocytes. Consequently, we have not been able to determine the 










analyzed the expression of Fgb in livers of mice fed a diet containing 0.5% cholate for 
1 week. The Fgb mRNA expression showed a tendency to be increased in livers of the 
CA-fed animals (1.3-fold) compared to animals fed control chow, however the 
difference was not significant (P=0.073), primarily due to small number of animals 
analyzed (control diet: n=6; cholate diet n=7). The relatively low induction level of 
Fgb does, however, not mean that this might not be physiological relevant. Also 
expression of Bsep was only increased 1.7-fold and this has previously been shown to 
result in a significant increase of hepatic bile salt secretion.33 
No candidate FXRE’s were detected in the promoter elements of the FGA and FGG 
genes even though the expression of both genes were increased by FXR and CDCA. 
The increased expression of FGA and FGG may however be caused by FGB, since it 
is known that overexpression of one of the Fibrinogen genes may stimulate expression 
of the other two genes.34 
Cholestatic liver diseases, like primary biliary cirrhosis and primary sclerosing 
cholangitis, are known to be associated with preserved clothing function or even a 
hypercoagulable state.35,36 This may explain the high incidence of portal vein 
thrombosis in primary biliary cirrhosis.35 The hypercoagulable state may in part offset 
the decreased synthesis of clothing factors during advanced liver cirrhosis. The study 
of Pihusch et al., showed increased Fibrinogen levels in primary biliary cirrhosis and 
primary sclerosing cholangitis patients.36 Our findings suggest that in cholestatic liver 
diseases fibrinogen synthesis is stimulated by bile salts, thus counteracting a decreased 
synthesis due to cirrhosis. This may aid the preservation of blood clothing in 
cholestatic liver disease. 
In conclusion, our results show that FGB transcription is positively regulated by FXR 
and bile salts. As such, it is another example showing that FXR transcriptional 
regulation is not restricted to genes involved in bile salt and cholesterol metabolism.  
Note: 
During finalizing this thesis, Anisfeld et al.37 also reported that FXR activates FGB 
gene transcription. Our results are largely in line with their study. In addition, they 
performed a promoter deletion analysis to locate the FXR response element (FXRE) 
in the human FGB promoter. They show that the region -2281/-1700 is required for 
FXR-induced transcription after activation by the synthetic ligand GW4064. This 
region does not contain a sequence that conforms to the currently known FXRE’s. 
Future experiments need to reveal which sequence in the FGB promoter directly binds 
FXR. 
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The liver is the second largest organ of the body and plays an important role in the 
metabolism of carbohydrates, fats, and proteins. It is the main producer of plasma 
proteins, like albumin and coagulation factors. It is also the organ involved in cleaning 
the body from toxic and waste products, eliminating a wide variety of these 
compounds predominantly via bile and feces. Bile is not only an escape route, but is 
also necessary for efficient digestion and absorption of dietary fats and fat-soluble 
vitamins. The driving force for bile formation is the hepatic synthesis and secretion of 
bile salts. After delivery into the intestine, bile salts are efficiently reabsorbed and 
returned to the liver. This shuttle of bile salts between the liver and intestine is called 
the  enterohepatic circulation of bile salts. Every cycle, a small portion (∼ 5%) of bile 
salts is lost via feces. De novo bile salt synthesis from cholesterol takes place in the liver 
parenchymal cells (hepatocytes) and substitutes for the fecal loss. Improper 
functioning of the enterohepatic circulation may lead to cholestasis, i.e. high serum 
levels of bile salts, and liver disease. 
The hepatocytes form a physical barrier between blood and bile. Bile salts and most 
other compounds cannot pass this barrier without the help of specialized transport 
systems. The hepatocyte houses various specific transport proteins located at the cell 
membrane, mediating the vectorial transport of compounds from blood to bile. For 
example, reabsorbed bile salts are taken up from the blood by members of the “solute 
carriers” superfamily. For secretion into bile, a steep bile salt concentration gradient 
must be overcome. This transport requires ATP hydrolysis and is accomplished by the 
Bile Salt Export Pump (also called ABCB11). 
Classically, bile salts are considered a detergent that is required to keep hydrophobic 
compounds, such as cholesterol or vitamins, in solution to aid in their excretion or 
absorption. Recent research has, however, shown that bile salts are also important 
signaling molecules. For instance, bile salts have been shown to regulate their own 
synthesis rate, as well as the transporters active in the enterohepatic circulation. They 
can bind to, and activate the transcription factor Farnesoid X Receptor (FXR), which 
in its turn regulates transcription of the genes that produce rate-limiting enzymes in 
the bile salt biosynthetic pathway, as well as the bile salt transporters. The Bile Salt 
Export Pump, bile salts and FXR are the central  topics of this thesis. In chapter 1, an 
overview is given of the current knowledge of hepatic transport proteins, their roles in 
inherited and acquired liver disease, and their function and regulation under normal 
and pathophysiological conditions. 
The D482G mutation results in a functional but 
unstable BSEP protein 
The inherited liver disease, Progressive Familial Intrahepatic Cholestasis type 2 
(PFIC2), is characterized by jaundice, itching, low biliary bile salt level, high serum bile 
salts level, but normal serum γ-glutamyltransferase (γ-GT) levels. These features imply 
that defective transport of bile salts from the hepatocyte into bile is the basis for this 










ABCB11 gene, which encodes for the hepatocanalicular bile salt export pump (BSEP). 
One of these PFIC2-causing mutations is studied in detail in chapter 2. The mutant 
protein harbors a glycine (G) residue at amino acid position 482 in stead of an 
aspartate (D), which is present at this position in the normal (wild type) protein. The 
rest of the 1,320 amino acids of both proteins are identical. We examined what the 
effect this specific mutation (D482G) is on bile salt transport activity, canalicular 
sorting and protein expression of BSEP. To study the effect on protein activity we 
expressed the murine Bsep protein in insect cells and performed ATPase and 
transport assays. Surprisingly, the mutation, which is located in one of the two ATP-
binding domains, did not abolish the ATPase nor the transport of the bile salt, 
taurocholate. To study the effect on protein sorting and expression, we expressed 
murine Bsep tagged with the Green Fluorescent Protein (GFP) in human hepatoma 
cells (HepG2). We observed that at physiological temperatures (37oC) the sorting as 
well as the protein expression were strongly effected. The GFP-Bsep[D482G] was not 
fully glycosylated and significant amounts of the protein were detected in the 
cytoplasm. In addition, the amount of GFP-Bsep[D482G] protein present was 
significantly lower compared to GFP-Bsep[WT] whereas the corresponding mRNA 
levels were 4 to 5-fold higher for GFP-Bsep[D482G] in the obtained stably transfected 
HepG2 cell lines. Lowering the culture temperature to 30oC increased the GFP-
Bsep[D482G] protein level to 4 to 5-fold compared to GFP-Bsep[WT], and resulted in 
efficiently targeted and fully glycosylated protein. These data demonstrated that the 
D482G mutation results in a still functional, but highly unstable BSEP protein. 
Therefore, PFIC2 patients, carrying this specific mutation, may benefit from therapies 
aimed at stabilization of the protein. 
Bile salts and FXR regulate BSEP transcription 
In chapter 3 the relationship between bile salts, FXR and the expression of the 
human ABCB11 gene (encoding BSEP) is described. HepG2 cells were incubated with 
the bile salt chenodeoxycholic acid (CDCA), which resulted in a 2-3 fold increased 
expression of ABCB11. The promoters of human and mouse ABCB11 were analyzed 
for regulatory elements and a candidate responsive element for the transcription factor 
FXR was found. We cloned the promoter region of the human ABCB11 gene 
containing this element and demonstrated that bile salts and FXR positively regulate 
ABCB11 promoter activity, leading to increased ABCB11 mRNA levels. Mutation of 
the FXR responsive element confirmed that this region in the ABCB11 promoter is 
responsible for bile salt-induced transcription of the ABCB11 gene. In addition, we 
showed that bile salts were unable to increase ABCB11 transcription, when the 
amount of endogenous FXR was reduced by RNA interference. We conclude that 
ABCB11 gene transcription is positively regulated by bile salts through activation of 
FXR. The level of ABCB11 transcription activation is dependent of the cellular 
amount of this transcription factor. 
Vitamin A is important for BSEP expression 
Bile salts facilitate the uptake of fat-soluble vitamins, including vitamin A, D, E and K. 










Vitamin A may be converted into 9-cis retinoic acid (9cRA) which is activating ligand 
for the transcription factor retinoid X receptor (RXR). RXR is another member of the 
superfamily of nuclear hormone receptors (NHRs) and functions as a key-regulator of 
gene transcription. It is a central dimerization partner for several NHRs, including 
FXR. 9cRA-activated RXR is considered to be a permissive partner of FXR, since 
both NHRs and both ligands are required for maximal induction of transcription of 
target genes, such as I-BABP and PLTP. In chapter 4 we investigate whether this is 
also true for ABCB11 gene transcription. Surprisingly, 9cRA reduced the bile salt-
induced ABCB11 mRNA expression in human hepatoma cells almost to control level. 
This effect of 9cRA is exerted via a decrease in binding of the FXR/RXR heterodimer 
to the FXR responsive element of the ABCB11 promoter. To determine whether the 
inhibition of ABCB11 expression by 9cRA plays a role in vivo, we generated vitamin A-
deficient (VAD) mice and determine the effect of bile salt feeding compared to 
control (normal vitamin A) mice. In VAD mice , Bsep (Abcb11) mRNA and protein 
expression was significantly more increased by bile salts (cholate) compare to bile salt-
fed control mice. We conclude that the vitamin A derivative 9cRA indeed plays an 
active role in the bile salt-dependent regulation of human and mouse 
ABCB11/Abcb11 transcription. The physiological rational behind this mechanism may 
be that at low vitamin A levels, bile salt secretion is increased to aid in the intestinal 
absorption of this vitamin. The treatment of cholestatic patients with vitamin A-
containing supplements, however, may need further exploration, since this may result 
in extra inhibition of BSEP expression, whereas the therapeutic goal would be the 
opposite. 
FXR is involved in transcription of non-bile salt related 
genes 
In the past few years, several genes have been shown to be transcriptionally regulated 
by FXR and bile salts. Most of them are involved in bile salt, cholesterol, and 
lipoprotein metabolism. FXR-target genes are however not restricted to these 
metabolic pathways, exemplified by the identification of Kininogen as a FXR-target. 
To get insight in genome-wide effects of bile salt-activated FXR, we performed a 
transcriptome analysis. This search for novel FXR and bile salt regulated genes is 
described in chapter 5. We generated a human hepatoma cell line, which stably 
overexpresses rat Fxr (HepG2-rFxr). These and the native cells were treated with the 
bile salt, chenodeoxycholic acid and mRNA expression of over 13.000 human genes 
were analyzed using microarrays. A novel candidate FXR-target gene was identified 
from this analysis, namely fibrinogen beta. Expression of this gene was induced in 
HepG2 cells by CDCA alone and superinduced in CDCA-treated HepG2-rFxr cells. 
Together with fibrinogen alpha and gamma, this protein forms fibrinogen, a plasma 
protein. It is synthesized in the liver and is involved in blood coagulation and possibly 
in the formation of liver fibrosis. Screening the conserved promoter regions of 
human, rat and murine fibrinogen beta for possible regulatory elements revealed a 
candidate FXR responsive element. Additional studies are necessary to firmly establish 
that this element is indeed responsible for the FXR and bile salt-dependent regulation 










Conclusions and perspectives 
During the past decade, important progress has been made in our understanding of 
the pathophysiology of cholestasis. Inherited disorders have been explained at the 
molecular level and were shown to be the result of mutations in enzymes involved in 
bile salt biosynthesis or transmembrane transporters involved in bile formation. 
Acquired cholestasis, for instance due to inflammation, is linked to disregulation of 
these proteins. The challenge of future research is to use this knowledge to develop 
successful therapies for cholestatic patients. The studies described in this thesis initiate 
such studies. We showed that a mutation in BSEP may cause PFIC-2 even though the 
protein product is a normally active bile salt export pump. The cause of the disease is 
due to a specific mutation in the BSEP gene that strongly reduces the BSEP protein 
level, most likely due to increased protein degradation. This phenomenon has also 
been described for several other inherited diseases. An important focus of research is 
therefore to define conditions or drug therapies that will maintain or increase the 
protein level of the mutant, but active protein in these patients. 
Novel targets to treat cholestasis are the transcription factors that regulate the levels 
of enzymes and transporters involved in the synthesis and enterohepatic circulation of 
bile salts. RXR and FXR are key players in this process. Endogenous and synthetic 
ligands for these transcription factors have been identified. Recent research, however, 
shows that the activation of FXR-target genes is ligand-dependent. In other words, a 
specific target gene may be activated by the endogenous ligand, CDCA, but not by the 
synthetic ligand GW4064. In addition, our own research shows that the ligand for 
RXR, 9-cis retinoic acid, in combination with bile salt-activated FXR, may 
simultaneously stimulate and inhibit expression of a subset of FXR-target genes. 
Therapies to treat cholestatic disease aimed at modulating the activity of these 
transcription factors therefore requires an in depth study of the effect of the 
(combination of the) individual ligands on human gene transcription. 
In the meantime, it should be noted that in a significant number of PFIC patients the 
genetic defect still has not been elucidated. Therefore, novel genes/proteins that are 
essential for bile salt homeostasis may be identified in the near future. 
Altogether, many challenges await us still to further understand the (molecular) causes 































Op de huid na is de lever het grootste orgaan van ons lichaam. De menselijke lever is 
ongeveer 1,5 kilo zwaar. Het is eigenlijk de chemische fabriek van ons lichaam. De 
functies van de lever zijn dan ook heel divers, maar kunnen grofweg in drieën worden 
opgesplitst: de vorming van gal, dat nodig is voor de spijsvertering, het onschadelijk 
maken en uitscheiden van lichaamseigen afvalstoffen en lichaamsvreemde stoffen 
(bijvoorbeeld medicijnen en giftige stoffen) en de stofwisseling van koolhydraten, 
vetten, eiwitten en hormonen. 
De cellen die deze functies uitoefenen zijn de hepatocyten. De lever bestaat voor het 
grootste deel uit deze cellen. Hepatocyten werken als een soort filter. Ze nemen 
allerlei stoffen op uit het bloed, en scheiden andere stoffen uit. Deze stoffen gaan òf 
(terug) naar het bloed òf naar de gal. Dit kan meestal niet zomaar, omdat elke 
lichaamscel door een zogenaamd celmembraan wordt omgeven. De celmembraan 
vormt een barrière voor veel stoffen. Om toch deze stoffen te kunnen opnemen en 
uitscheiden, maakt de hepatocyt gebruik van eiwitten die in de celmembraan zitten en 
die deze stoffen over de membraan kunnen transporteren: de transporteiwitten. Een 
hepatocyt grenst zowel aan een bloedvaatje, de zogenaamde sinusoïde, als aan een 
galkanaaltje, dat de gal afvoert naar de galblaas. Het gedeelte van de celmembraan dat 
grenst aan het bloed wordt de sinusoïdale membraan genoemd, en het gedeelte van de 
celmembraan dat aan het gal grenst, wordt de canaliculaire membraan genoemd. Via 
de sinusoïdale membraan worden stoffen opgenomen uit het bloed, maar ook 
afgegeven aan het bloed. Via de canaliculaire membraan worden stoffen uitgescheiden 
naar de gal. Elk transporteiwit is gespecialiseerd in het transporteren van bepaalde 
stoffen en zit in één van de membranen. Als deze transportprocessen niet goed 
functioneren, kan dit resulteren in (lever)ziekte. Hierbij ontstaat vaak een stapeling van 
bepaalde stoffen in het bloed en de lever die niet goed naar de gal getransporteerd 
worden. Een bekend voorbeeld hiervan is geelzucht, waarbij het transport van 
bilirubine naar de gal is verstoord. Door de hoge concentraties bilirubine in het bloed 
ontstaat de gele (huids)kleur. Dit is echter een relatief onschuldige conditie omdat 
bilirubine zelf geen toxische effecten heeft. Andere galcomponenten, zoals galzouten 
of fosfolipiden, zijn wel zeer schadelijk als deze niet goed naar de gal worden 
uitgescheiden. In dit proefschrift is vooral het belang en de regulatie van 
galzouttransport naar de gal geanalyseerd. Hoofdstuk 1 beschrijft de huidige stand 
van zaken wat betreft de kennis over transporteiwitten van de hepatocyt die betrokken 
zijn bij galvorming. Speciale aandacht wordt gegeven aan de eiwitten die galzouten 
transporteren en de mechanismen die de hoeveelheid en activiteit van deze eiwitten 
bepalen. 
Eén van deze eiwitten wordt uitgebreider bestudeerd in de volgende drie 
hoofdstukken: de Bile Salt Export Pump, afgekort BSEP. Deze galzoutexportpomp 
komt alleen in de lever voor en zit in de canaliculaire membraan. Daar is dit eiwit 
verantwoordelijk voor het transport van galzouten uit de hepatocyt naar de gal. Gal 
bestaat voor het grootste deel uit water en voor het overige uit opgeloste stoffen, 
waaronder de galzouten. Galzouten spelen een belangrijke rol bij de vertering van 










voor dat deze stoffen in de darmen in oplossing blijven, zodat ze beter opgenomen 
kunnen worden door de darmcellen. Hiermee zijn ze essentieel voor de uitscheiding 
van "giftige" verbindingen. Tegelijkertijd zijn ze ook belangrijk voor de opname van 
vetachtige voedingsstoffen in de darm, zoals vitaminen (A, D, E en K). De lever is de 
enige plaats in het lichaam waar galzouten gemaakt worden. Dit is een ingewikkeld 
proces waarbij cholesterol wordt omgezet in galzouten. Vervolgens worden ze in een 
galkanaaltje uitgescheiden en komen ze uiteindelijk terecht in hun opslagplaats, de 
galblaas. Wanneer galzouten nodig zijn voor de vertering van vettige voedingsstoffen 
worden ze met de gal uitgescheiden in de darm. Ons lichaam gaat heel zuinig om met 
de galzouten. Het merendeel wordt dan ook weer opgenomen door de darmcellen en 
worden via het bloed weer teruggevoerd naar de lever. De hepatocyten nemen de 
galzouten uit het bloed op om ze weer te kunnen uitscheiden in het galkanaaltje. De 
route die de galzouten afleggen tussen darmen en lever wordt de enterohepatische 
kringloop van galzouten genoemd (entero = darmen; hepatisch = lever). Deze 
kringloop wordt in stand gehouden door transporteiwitten in de darm en in de lever, 
waaronder BSEP. Wanneer deze kringloop wordt verstoord, bijvoorbeeld door een 
defect in BSEP, is er sprake van cholestase. 
De D482G-mutatie leidt tot een functioneel maar 
instabiel BSEP-eiwit 
Kinderen met de erfelijke leverziekte "Progressive Familial Intrahepatic Cholestasis" 
type 2 (PFIC2) hebben vanaf hun geboorte cholestase, die vervolgens alleen maar 
erger wordt.. Bij PFIC2 kunnen er geen galzouten van de hepatocyt naar het 
galkanaaltje getransporteerd worden, omdat door fouten of mutaties in het gen van 
BSEP er geen (goed) eiwit gemaakt kan worden. Het gevolg is dat galzouten zich 
ophopen in de levercellen en in het bloed. Een belangrijk symptoom van cholestase is 
jeuk. Bij deze erfelijke vorm van cholestase uit dit zich echter ook in groeiachterstand 
van deze patiëntjes, omdat voedingsstoffen niet goed opgenomen kunnen worden 
door het tekort aan galzouten in de gal. Bovendien raakt hun lever door de giftige 
werking van de overmaat aan galzouten in de levercellen zodanig beschadigd dat de 
lever getransplanteerd moet worden. Er zijn verschillende mutaties van het BSEP-gen 
bekend en in hoofdstuk 2 onderzoeken we één van die mutaties: de D482G-mutatie. 
Deze code betekent dat van de 1321 aminozuren waar het BSEP-eiwit uit bestaat er 1 
anders is dan normaal. Op positie 482 is een glycine (G) aanwezig in plaats van het 
normale aspartaat (D). We hebben in de eerste plaats gekeken of een BSEP-eiwit met 
deze mutatie nog wel galzouten kan transporteren. Dat was het geval, dus dit kan niet 
de reden zijn waarom deze patiëntjes cholestase krijgen. Vervolgens bestudeerden we 
de vorming van het eiwit zelf. Door de D482G-mutatie bleek er veel minder BSEP-
eiwit gevormd te worden en dit beetje komt ook nog niet eens allemaal op de goede 
plek (canaliculaire membraan) terecht. In het laboratorium hebben we kunnen 
vaststellen dat bij een lage temperatuur het D482G-BSEP-eiwit wel goed gevormd 
wordt. Dit alles betekent dat de D482G-mutatie niet leidt tot functieverlies van BSEP, 
want het eiwit kan nog wel galzouten transporteren. Echter, door deze ene mutatie 










galzouten efficiënt naar de gal te transporteren. Waarschijnlijk wordt het eiwit herkend 
als “fout” en daardoor snel afgebroken. 
Deze studie heeft aangetoond dat het mutante eiwit wel zijn normale functie kan 
uitvoeren. In de toekomst zou het dus mogelijk kunnen zijn dat er therapieën worden 
ontwikkeld die gericht zijn om de versnelde afbraak van het mutante eiwit tegen te 
gaan. Dit is niet geheel ondenkbaar, aangezien ditzelfde mechanisme is beschreven 
voor verschillende andere erfelijke aandoeningen, onder andere bij taaislijmziekte. Het 
is wellicht mogelijk om deze verschillende aandoeningen met eenzelfde 
medicijn/therapie te behandelen. 
Galzouten reguleren de expressie van BSEP met behulp 
van FXR 
Tot voor kort werden galzouten alleen gezien als “oplosmiddel” voor vetachtige 
verbindingen die daarmee efficiënt uitgescheiden of juist opgenomen kunnen worden. 
Echter, in de afgelopen jaren is gebleken dat galzouten ook zeer belangrijke 
signaalmoleculen zijn. Zo reguleren ze zelf dat de enterohepatische kringloop in stand 
gehouden wordt door voortdurend de synthese van galzouten en het transport ervan 
in lever en darm op elkaar af te stemmen. De synthese wordt verhoogd als de 
concentraties van galzouten in de lever laag zijn. Transport van galzouten naar de gal 
wordt verhoogd als de concentraties ervan in de lever verhoogd zijn. Het moleculaire 
mechanisme van deze regulatie blijkt voornamelijk te liggen in het aansturen van 
gentranscriptie. Galzouten zijn liganden van de transcriptiefactor Farnesoid X 
receptor of FXR. FXR dat geactiveerd is door galzouten reguleert de transcriptie van 
genen die coderen voor eiwitten die galzouten transporteren en enzymen die 
betrokken zijn bij de synthese van galzouten. In hoofdstuk 3 wordt aangetoond dat 
galzouten ook de expressie van humaan BSEP reguleren. Deze activeren FXR, die 
samen met de transcriptiefactor Retinoic X Receptor of RXR de transcriptie van 
BSEP verhoogt. FXR en RXR binden als zogenaamde heterodimeer samen aan een 
specifieke DNA-sequentie, de FXRE, in de promoter van het BSEP-gen. De door 
galzouten gestimuleerde expressie van BSEP wordt tenietgedaan als de FXRE in de 
BSEP promoter is gemuteerd. Als met behulp van de techniek van RNA-interferentie 
de hoeveelheid FXR wordt verlaagd, is eveneens de galzout-geïnduceerde expressie 
van BSEP afwezig. Deze resultaten laten zien dat ook bij de mens, de 
galzoutexportpomp BSEP wordt gereguleerd door activering van FXR door 
galzouten. 
Vitamine A is belangrijk voor de expressie van BSEP 
Als vervolg op hoofdstuk 3 hebben we in hoofdstuk 4 bepaald of 9-cis retinolzuur 
(9cRA), dat een ligand is van RXR, ook een rol speelt bij de regulatie van de 
transcriptie van het BSEP-gen. 9cRA wordt gevormd uit vitamine A. Vitamine A is 
een vetachtige vitamine en galzouten zijn belangrijk voor de opname ervan in de 
darm. Vitamine A is belangrijk voor verschillende processen in ons lichaam, 
bijvoorbeeld het gezichtsvermogen. Een bekend gevolg van tekort aan vitamine A is 










embryo en de voortplanting. Van verschillende genen die door FXR en RXR 
gereguleerd worden is bekend dat de aanwezigheid van beide liganden, galzouten en 
9cRA, zorgt voor de sterkste expressie. Wij hebben ontdekt dat dit niet het geval is 
voor BSEP. Sterker nog: 9cRA lijkt juist een remmende werking te hebben. Dus 
wanneer beide transcriptiefactoren én beide liganden aanwezig zijn wordt er minder 
BSEP gemaakt dan met alleen galzouten en beide transcriptiefactoren. We hebben dit 
aangetoond zowel in in vitro experimenten, met humane cellijnen, als in in vivo 
experimenten met muizen. De muizen kregen 12 weken voer waarin geen vitamine A 
zat. Vervolgens kregen ze 1 week lang ook nog galzouten toegevoegd aan hun voer. In 
totaal werden 4 groepen muizen vergeleken: muizen met een tekort aan vitamine A 
(VAD-muizen) die 1 week wel of geen galzouten in het voer kregen en 
controlemuizen (géén tekort aan vitamine A) die eveneens 1 week wel of geen 
galzouten in het voer kregen. Zoals verwacht werd in de levers van de VAD-muizen 
met galzouten in de voeding de hoogste BSEP-expressie waargenomen. Deze 
resultaten laten zien dat vitamine A een belangrijke factor is in de regulatie van 
galzouthomeostase. Patiënten met cholestase hebben vaak ook een laag vitamine A-
gehalte. De cholestase kan een gevolg zijn van een te lage BSEP-expressie. Het 
behandelen van deze patiënten met vitamine A-houdende preparaten kan echter de 
expressie van BSEP nog verder verlagen en daarmee de cholestase verergeren. 
FXR beïnvloedt ook de expressie van niet-
galzoutgerelateerde genen 
Van verschillende eiwitten is al bekend dat hun expressie gereguleerd wordt door 
galzouten en FXR (samen met RXR en 9cRA). Toch komen er nog steeds nieuwe bij. 
In hoofdstuk 5 passen we een nieuwe techniek toe, de microarray-technologie, op 
zoek naar eiwitten die ook door galzouten en FXR gereguleerd worden. De 
microarray-technologie maakt gebruik van een chip waarop alle genen van alle eiwitten 
van, bijvoorbeeld, de mens zitten. Met deze technologie kun je bestuderen wat er met 
de expressie van alle genen gebeurt, wanneer er bijvoorbeeld meer galzouten en FXR 
aanwezig zijn. Dit hebben we dan ook gedaan en we hebben ontdekt dat mogelijk 
Fibrinogeen Bβ (FGB) door galzouten en FXR wordt gereguleerd. In tegenstelling tot 
de meeste andere FXR-targetgenen lijkt dit eiwit geen rol te spelen in de 
galzouthuishouding. FGB vormt samen met Fibrinogeen Aα (FGA) en Fibrinogeen γ 
(FGG) het eiwit Fibrinogeen. De expressie van de FGA en FGG wordt, zij het in 
minder mate dan FGB, ook verhoogd door galzouten en FXR. Fibrinogeen wordt in 
de lever gemaakt en is belangrijk voor de bloedstolling. Het is mogelijk dat 
Fibrinogeen een rol speelt bij littekenvorming (fibrose) in de lever. Fibrose is een 
reactie van de lever op weefselschade, bijvoorbeeld door de giftige effecten van een 
overmaat aan galzouten in de lever bij cholestase. De effecten van galzouten en FXR 
op de expressie van deze drie eiwitten moeten echter nog nader bestudeerd worden 











Conclusies en perspectieven 
De afgelopen jaren is onze kennis van de cellulaire processen die cholestase 
veroorzaken sterk toegenomen. Erfelijke aandoeningen die resulteren in chronische 
cholestase zijn tot op moleculair niveau uitgezocht: ze zijn het resultaat van mutaties 
in eiwitten die een rol spelen in de galzouthuishouding, zoals enzymen in de lever die 
galzouten maken en eiwitten in lever- en darmcellen die galzouten de cel in of uit 
transporteren. Cholestase kan ook vele andere, niet-genetische, oorzaken hebben, 
bijvoorbeeld een ontsteking in de lever. Het blijkt dat dan de hoeveelheid 
galzoutvormende enzymen en/of de galzouttransporters niet goed is gereguleerd. De 
wetenschappelijke uitdaging is nu om deze kennis te gebruiken voor de ontwikkeling 
van nieuwe behandelmethoden voor patiënten met cholestase. Het werk beschreven 
in dit proefschrift geeft hiervoor een eerste aanzet. We hebben laten zien dat sommige 
PFIC2-patiënten een mutatie in het BSEP-gen hebben die de functie van deze 
transporter niet aantast. Toch hebben deze patiënten cholestase. Dit wordt 
waarschijnlijk veroorzaakt doordat het mutante BSEP-eiwit in de levercel herkend 
wordt als "fout" en versneld wordt afgebroken. Hierdoor kan er niet voldoende 
galzouttransport naar de gal plaatsvinden en ontstaat er cholestase. Verschillende 
andere erfelijke ziekten (bijvoorbeeld taaislijmziekte) blijken een vergelijkbare oorzaak 
te hebben; er is te weinig van het mutante, maar wel functionele, eiwit. Een belangrijk 
speerpunt van toekomstig onderzoek is dan ook om behandelmethoden te 
ontwikkelen die de hoeveelheid van het mutante eiwit naar een voldoende niveau 
brengen. 
Sinds een aantal jaren is er ook een volledig nieuwe groep van eiwitten geïdentificeerd 
waarop behandeling van cholestase gericht kan zijn. Dit zijn de transcriptiefactoren 
die de hoeveelheid galzoutproducerende enzymen en galzouttransporters reguleren. 
FXR en RXR zijn hiervoor de belangrijkste "targets". Verschillende natuurlijke en 
synthetische liganden die deze transcriptiefactoren activeren zijn al voorhanden. Uit 
recent onderzoek blijkt echter dat het effect van FXR op de regulatie van eiwitten 
afhankelijk is van het gebruikte ligand. Met andere woorden, het natuurlijke ligand van 
FXR, het galzout CDCA, leidt tot een verhoging van de expressie van een bepaald 
FXR-"target"eiwit, terwijl dit niet gebeurt met het synthetische ligand GW4064. 
Bovendien laten wij in dit proefschrift zien dat het ligand van RXR, het vitamine A-
derivaat 9-cis retinolzuur, in combinatie met FXR en galzouten op hetzelfde moment 
de expressie van een aantal FXR-"target"-genen verhoogt terwijl dat van andere FXR-
"target"-genen wordt verlaagd. Het is daarom van belang om de effecten van de 
verschillende (en ook combinaties van) liganden grondig te onderzoeken alvorens men 
een behandeling kan starten die is gebaseerd op de manipulatie van deze 
transcriptiefactoren. 
Ondertussen moeten we ons ook realiseren dat er nog steeds een groep patiënten met 
PFIC is waarvan we de genetische oorzaak niet weten. Dit betekent dat er nog steeds 
nieuwe genen/eiwitten ontdekt zullen worden die een rol spelen in de 
galzouthuishouding. Ook deze nieuwe factoren kunnen van groot belang zijn bij het 
ontstaan van cholestase als gevolg van niet-genetische componenten zoals ontsteking, 
medicijnen, alcohol, drugs, enzovoort. Daarom is het belangrijk om naar deze 










Concluderend kan gesteld worden dat er nu verschillende eiwitten bekend zijn waarop 
nieuwe behandelmethoden voor patiënten met cholestase gericht kunnen zijn. De 
toekomst moet uitwijzen of hiermee efficiënte en veilige therapieën ontwikkeld 
kunnen worden. Met andere woorden, er is nog genoeg onderzoek te doen om meer 































Dit proefschrift zou als motto kunnen hebben “beter laat dan nooit”, want het heeft 
wel erg lang geduurd voordat mijn promotieonderzoek geheel was afgerond. Maar nu 
is het eindelijk zo ver en kan ik middels dit dankwoord iedereen bedanken voor de 
vriendschap, collegialiteit en betrokkenheid die ik tijdens mijn jaren bij MDL heb 
ervaren. 
 
Zonder (co-)promotor geen promotie: dankjewel Peter en Klaas Nico voor jullie 
begeleiding! Peter, waarschijnlijk weet je dit niet, maar telkens na overleg met jou over 
onder andere rare resultaten zag ik weer licht aan het einde van de onderzoekstunnel. 
Klaas Nico, je bent halverwege mijn AIO-tijd bij MDL in het diepe gegooid. 
Dankjewel voor je dagelijkse begeleiding die geresulteerd heeft in een proefschrift 
waar ik tevreden mee ben. 
 
De twee personen die ik bijzonder veel dank verschuldigd ben zijn Janette en Mariska. 
Heel erg bedankt voor al het werk dat jullie verzet hebben, maar meer nog voor jullie 
interesse in mijn wel en wee tijdens mijn AIO-jaren. Ik ben blij dat jullie mij ook nog 
tijdens de laatste loodjes, de openbare verdediging, terzijde willen staan. 
 
Han, mijn andere MDL-baas. Na het vertrek van Olaf en Michael nam jij Janette en 
mij onder je hoede en konden we verder met ons onderzoek. Heel erg bedankt. 
 
Olaf en Michael hebben het onderzoeksvoorstel van dit promotieonderzoek 
geschreven, maar verlieten MDL nog voordat het was afgerond. Olaf, bedankt voor je 
begeleiding tijdens de beginperiode en je tip om RNAi te gebruiken voor hoofdstuk 3. 
Michael, jij ook bedankt voor je begeleiding en voor het beoordelen van mijn 
proefschrift als lid van de beoordelingscommissie. Aansluitend wil ik ook de andere 
twee leden bedanken, Folkert Kuipers (ook nog bedankt voor je hulp bij en interesse 
in mijn enige dierproef) en Ronald Oude Elferink. 
 
De rest van de MDL'ers wil ik natuurlijk ook bedanken voor hun collegialiteit en 
vriendschap tijdens en na het werk. Ik had geen betere collega's kunnen wensen: 
Antonella (dankjewel voor je hulp in mijn laatste jaar, steun en belangstelling), Hans B. 
(zo gek als een deur (ik kan het niet laten), maar een ontzettend fijne collega (nou, als 
dit geen fantastisch compliment is...hier moet je jaren mee vooruit kunnen)), Gerard, 
het apoptoseclubje: Marieke (bedankt voor je luisterend oor en voor het 
beantwoorden van al mijn mailtjes van de laatste tijd), Manon (dankjewel voor het 
regelen van de bioscoopkaartjes en gebruik van je pc), Laura, Lisette en Titia. De 
studenten Duncan (ik vond het fijn om jou te begeleiden, hartstikke bedankt voor je 
hulp bij hoofdstuk 4), Geeske en Joost (allebei heel erg bedankt voor jullie hulp bij 
hoofdstuk 3, het was altijd een stuk gezelliger in de celkweek met jullie geklep erbij). 
De MDL-secretaresses: Gonny (dankjewel voor al je hulp) en Petra. En natuurlijk de 
oud-MDL'ers Rob, Guido, Alexandra, Janneke, Jenny, Johan, en Hans K. 
 
Natuurlijk wil ik ook iedereen van Kindergeneeskunde bedanken voor hun 










Tineke, Anniek en Jelske (we, maar vooral jeweetwel, hebben flink genoten van de 
snoeppot), Juul (bedankt voor je hulp tijdens onze dierproef, maar ook voor je 
betrokkenheid), de vraagbaken Henk en Vincent, Nicolette en Janny (jullie discussies 
waren prachtig om aan te horen, met jullie hulp hebben we de labdag nieuw leven in 
kunnen blazen) en niet te vergeten Fjodor (met je subtiele en uiterst droge humor 
rondom het real time PCR-gebeuren). 
 
Onderzoek doen gaat gepaard met veel frustraties, maar gelukkig kon ik flink klagen 
bij mijn vrienden: middelbare-schoolvriendin Chantal en Harry; de "bioloogjes" met 
aanhangers: Manon en Diallo, Odette en Peter en Saskia en Anne; de "huisgenoten" 
met aanhangers: Marcel en Ilona, Frans en Fenneke en Izhar en Sara; en "Barger 
Compas": Joerik en Sjanien. 
 
Dan kom ik nu bij de belangrijkste personen in mijn leven: mijn familie. 
Parpsjen en Moesje, bedankt dat jullie altijd voor mij en ons klaarstaan. Ik had geen 
betere ouders kunnen wensen. 
Pa en Ma Suelmann, Linda en André en Han en Nienke, als we hulp nodig hebben 
staan jullie altijd voor ons klaar, dankjewel! 
De veerkrachtigste mensen die ik ken zijn mijn broer Robert en schoonzus Astrid. 
Rob, fijn dat je mijn broer bent! 
 
En als laatste mijn maatje voor het leven: Christian. Kris, woorden kunnen niet 
beschrijven wat ik voor je voel, maar gelukkig weet je dat wel. We hebben met z'n 
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